Soleno Therapeutics (SLNO) S-14 May 15IPO registrationFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
Document and Entity Information	Mar. 31, 2015
Document Information [Line Items]
Document Type	S-1
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Trading Symbol	CAPN
Entity Registrant Name	Capnia, Inc.
Entity Central Index Key	1484565
Entity Filer Category	Smaller Reporting Company

Condensed_Balance_Sheets

Condensed Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Current assets
Cash and cash equivalents	$9,529,000	$7,956,710	$1,268,770
Restricted cash	20,000	20,000	20,000
Accounts receivable	8,000		149,605
Inventory	206,000	109,336
Prepaid expenses and other current assets	260,000	252,272	85,149
Total current assets	10,023,000	8,338,318	1,523,524
Long-term assets
Property and equipment, net	44,000	57,607	63,167
Total assets	10,067,000	8,395,925	1,586,691
Current liabilities
Accounts payable	621,000	986,799	57,721
Accrued compensation and other current liabilities	438,000	201,457	128,651
Line of credit and accrued interest		101,529
Convertible promissory notes and accrued interest			13,991,857
Total current liabilities	1,059,000	1,289,785	14,178,229
Commitments (Note 10)
Long-term liabilities
Total long-term liabilities	20,311,000	18,296,093	1,464,877
Convertible Preferred Stock
Total liabilities	21,370,000	19,586,000
Stockholders' deficit
Common stock, value	7,000	6,769	536
Additional paid-in-capital	70,679,000	59,141,404	19,235,512
Accumulated deficit	-81,989,000	-70,338,126	-57,100,511
Total stockholders' deficit	-11,303,000	-11,189,953	-37,864,463
Total liabilities and stockholders' deficit	10,067,000	8,395,925	1,586,691
Series A Convertible Preferred Stock [Member]
Convertible Preferred Stock
Convertible preferred stock			1,500,000
Stockholders' deficit
Total stockholders' deficit		0	1,500,000
Series B Convertible Preferred Stock [Member]
Convertible Preferred Stock
Convertible preferred stock			6,862,939
Stockholders' deficit
Total stockholders' deficit		0	6,862,939
Series C Convertible Preferred Stock [Member]
Convertible Preferred Stock
Convertible preferred stock			15,445,109
Stockholders' deficit
Total stockholders' deficit		0	15,445,109
Series A Warrant liability [Member]
Long-term liabilities
Convertible preferred stock warrant liability	3,582,000	857,362
Series B Warrant liability [Member]
Long-term liabilities
Convertible preferred stock warrant liability	14,180,000	17,438,731
Series C Warrant liability [Member]
Long-term liabilities
Convertible preferred stock warrant liability	$2,549,000		$1,464,877

Condensed_Balance_Sheets_Paren

Condensed Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Convertible preferred stock, shares authorized		1,860,000
Convertible preferred stock, shares outstanding		865,429
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	100,000,000	10,000,000
Common stock, shares issued	6,769,106	535,685
Common stock, shares outstanding	6,769,106	535,685
Series A Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$0.00	$0.00
Convertible preferred stock, shares authorized	40,000	40,000
Convertible preferred stock, shares issued	0	31,250
Convertible preferred stock, shares outstanding	0	31,250
Convertible preferred stock, aggregate liquidation preference	$1,500,000	$1,500,000
Series B Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$0.00	$0.00
Convertible preferred stock, shares authorized	320,000	320,000
Convertible preferred stock, shares issued	0	119,140
Convertible preferred stock, shares outstanding	0	119,140
Convertible preferred stock, aggregate liquidation preference	6,862,939	6,862,939
Series C Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$0.00	$0.00
Convertible preferred stock, shares authorized	1,500,000	1,500,000
Convertible preferred stock, shares issued	0	715,039
Convertible preferred stock, shares outstanding	0	715,039
Convertible preferred stock, aggregate liquidation preference	$15,445,109	$15,445,109

Condensed_Statements_of_Operat

Condensed Statements of Operations and Comprehensive Loss (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Revenue	$22,000			$3,000,000
Cost of revenue	18,000
Gross profit	4,000
Expenses
Research and development	878,000	372,000	2,242,216	2,379,832
Sales and marketing	260,000		252,359
General and administrative	1,292,000	312,000	2,665,154	1,466,951
Total expenses	2,430,000	684,000	5,159,729	3,846,783
Operating income (loss)	-2,426,000	-684,000	-5,159,729	-846,783
Interest and other income (expense)
Interest income			1,085	1,772
Interest (expense)	-1,000	-388,000	-4,130,394	-2,860,267
Change in fair value of warrants liabilities	-6,174,000	246,000	-3,941,335	-105,320
Inducement charge for Series C warrants	-3,050,000
Other income (expense)		-8,000	-3,948,578	-1,965
Net loss	($11,651,000)	($834,000)	($13,237,616)	($3,707,243)
Basic and diluted net loss per common share	($1.67)	($1.56)	($10.42)	($6.92)
Weighted-average common shares outstanding used to calculate basic and diluted net loss per common share	6,965,483	535,685	1,270,033	535,648

Statements_of_Convertible_Pref

Statements of Convertible Preferred Stock and Stockholders' Deficit (USD $)	Total	2010 and 2012 Convertible Promissory Notes [Member]	2014 Convertible Promissory Notes [Member]	Series A Convertible Preferred Stock [Member]	Series B Convertible Preferred Stock [Member]	Series C Convertible Preferred Stock [Member]	Series A & B Warrants [Member]	Series B Warrant liability [Member]	Series B Warrant liability [Member]	Series B Warrant liability [Member]	Series B Warrant liability [Member]	Series A Warrant liability [Member]	Common Stock [Member]	Common Stock [Member]	Common Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Additional Paid-In Capital [Member]	Additional Paid-In Capital [Member]	Additional Paid-In Capital [Member]	Additional Paid-In Capital [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Accumulated Deficit [Member]
	USD ($)	USD ($)	USD ($)	USD ($)	USD ($)	USD ($)	USD ($)	USD ($)	Series A Convertible Preferred Stock [Member]	Series B Convertible Preferred Stock [Member]	Series C Convertible Preferred Stock [Member]	USD ($)	USD ($)	2010 and 2012 Convertible Promissory Notes [Member]	2014 Convertible Promissory Notes [Member]	Series B Warrant liability [Member]	USD ($)	2010 and 2012 Convertible Promissory Notes [Member]	2014 Convertible Promissory Notes [Member]	Series A & B Warrants [Member]	Series B Warrant liability [Member]	Series A Warrant liability [Member]	USD ($)	Series B Warrant liability [Member]
														USD ($)	USD ($)			USD ($)	USD ($)	USD ($)	USD ($)	USD ($)
Balances at beginning, Amount at Dec. 31, 2012	($34,195,637)			$1,500,000	$6,862,939	$15,445,109							$522				$19,197,109						($53,393,268)
Balances at beginning, Shares at Dec. 31, 2012				31,250	119,140	715,039							522,360
Vesting of restricted common stock	23,986												14				23,972
Vesting of restricted common stock, Shares													13,325
Stock-based compensation	14,431																14,431
Net loss	-3,707,243																						-3,707,243
Balances at end, Amount at Dec. 31, 2013	-37,864,463			1,500,000	6,862,939	15,445,109							536				19,235,512						-57,100,511
Balances at end, Shares at Dec. 31, 2013				31,250	119,140	715,039							535,685
Stock-based compensation	345,435																345,435
Conversion of preferred stock to common stock in IPO	23,808,048			-1,500,000	-6,862,939	-15,445,109							865				23,807,183
Conversion of preferred stock to common stock in IPO, shares				-31,250	-119,140	-715,039							865,429
Stock warrant liability reclassification/Issuance of warrants for overallotment exercise	1,220,718						18,975										1,220,718			18,975
Issuance of common stock in IPO (net of discounts & commission of $861,948)	9,846,552												1,650				9,844,902
Issuance of common stock in IPO (net of discounts & commission of $861,948), Shares													1,650,000
Beneficial conversion feature in connection with related party convertible promissory notes	1,723,984																1,723,984
Conversion of notes payable into common stock in IPO		15,410,110	2,512,119											3,166	552			15,406,944	2,511,567
Conversion of notes payable into common stock in IPO, Shares														3,165,887	552,105
Deferred IPO costs	-1,830,450																-1,830,450
Series A warrants treated as liability								-11,649,106				-1,494,259									-11,649,106	-1,494,259
Series B warrants treated as derivative liability, Shares								0	0	0	0					0					0			0
Net loss	-13,237,616																						-13,237,616
Balances at end, Amount at Dec. 31, 2014	($11,189,953)			$0	$0	$0							$6,769				$59,141,404						($70,338,127)
Balances at end, Shares at Dec. 31, 2014				0	0	0							6,769,106

Statements_of_Convertible_Pref1

Statements of Convertible Preferred Stock and Stockholders' Deficit (Parenthetical) (USD $)	12 Months Ended
	Dec. 31, 2014
Issuance of common stock in IPO, discounts & commission	$861,948

Condensed_Statements_of_Cash_F

Condensed Statements of Cash Flows (USD $)	3 Months Ended		12 Months Ended
Condensed Statements of Cash Flows (USD $)	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net loss	($11,651,000)	($834,000)	($13,237,616)	($3,707,243)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	15,000	7,000	28,516	42,114
Stock-based compensation expense	401,000	11,000	345,435	38,417
Loss on disposition of property and equipment		8,000	7,727	1,446
Change in fair value of stock warrants	6,174,000	-246,000	3,941,335	105,320
Non-cash interest expense relating to convertible promissory notes & amortization of discount on notes			4,128,863	2,860,267
Inducement charge for Series C warrants	3,050,000
Non-cash interest expense relating to line of credit			1,529
Non-cash interest expense relating to warrants and convertible promissory notes		388,000
Change in operating assets and liabilities:
Accounts receivable	-8,000	150,000	149,605	-149,605
Inventories	-97,000		-109,336
Other receivables		-41,000		150,782
Prepaid expenses and other assets	-7,000	-77,000	-167,123	-2,557
Accounts payable	199,000	31,000	353,897	-161,803
Accrued compensation & other current liabilities			72,806	-62,356
Accrued liabilities	115,000	94,000
Net cash used in operating activities	-1,809,000	-509,000	-4,484,362	-885,218
Cash flows from investing activities:
Proceeds from sale of property and equipment		4,000
Purchase of property and equipment	-1,000		-30,683	-1,274
Net cash (used in) provided by investing activities	-1,000	4,000	-30,683	-1,274
Cash flows from financing activities:
Proceeds from issuance of preferred stock warrants			1,946
Proceeds from exercise of common stock options	12,000
Proceeds from issuance of convertible notes payable			2,490,781
Proceeds from line of credit			100,000
Proceeds from Initial Public Offering			10,727,475
Initial Public Offering costs paid	-530,000		-2,117,217
Repayment of credit line	-102,000
Net cash provided by financing activities	3,382,000		11,202,985
Net increase (decrease) in cash and cash equivalents	1,572,000	-505,000	6,687,940	-886,492
Cash and cash equivalents, beginning of period	7,956,710	1,268,770	1,268,770	2,155,262
Cash and cash equivalents, end of period	9,529,000	764,000	7,956,710	1,268,770
Supplemental disclosures of noncash investing and financing information
Initial Public Offering costs accrued and included in Accounts Payable			575,181
Issuance of restricted common stock in exchange for intellectual property				23,986
Beneficial conversion feature related to the warrants to purchase shares of convertible preferred stock in connection with convertible promissory notes			1,723,984
Issuance of warrants for the purchase of convertible preferred stock in connection with notes payable			966,978
Supplemental disclosures of noncash investing and financing information
Reduction in initial public offering costs payable	45,000
Cashless exercise of 2010/2012 warrants	13,000
Series A Warrant liability [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of stock warrants	-2,800,000
Cash flows from financing activities:
Proceeds from exercise of warrants	156,000
Series A Warrant liability [Member] \| Cash Exercise [Member]
Supplemental disclosures of noncash investing and financing information
De-recognition warrant liability	42,000
Private Placement Series B Warrants [Member]
Cash flows from financing activities:
Proceeds from exercise of warrants	3,832,000
Other Series B Warrants [Member]
Cash flows from financing activities:
Proceeds from exercise of warrants	189,000
Series B Warrant liability [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of stock warrants	-1,500,000
Cash flows from financing activities:
Series B warrant transaction costs paid	-175,000
Supplemental disclosures of noncash investing and financing information
Warrant transaction costs accrued and included in accrued compensation and other current liabilities	131,000
Series B Warrant liability [Member] \| Cash Exercise [Member]
Supplemental disclosures of noncash investing and financing information
De-recognition warrant liability	6,748,000
Series B Warrant liability [Member] \| Cash Less Exercise [Member]
Supplemental disclosures of noncash investing and financing information
De-recognition warrant liability	417,000
Series B Warrant liability [Member] \| Warrants contributed back to the company [Member]
Supplemental disclosures of noncash investing and financing information
De-recognition warrant liability	3,000
IPO [Member] \| Series A Warrant liability [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of stock warrants			636,897
IPO [Member] \| Series B Warrant liability [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of stock warrants			-5,789,625
IPO [Member] \| 2014 Convertible Promissory Notes [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash interest expense relating to convertible promissory notes & amortization of discount on notes			1,855,452
Supplemental disclosures of noncash investing and financing information
Notes payable converted into common stock in IPO			2,512,119
IPO [Member] \| 2010 and 2012 Convertible Promissory Notes [Member]
Supplemental disclosures of noncash investing and financing information
Notes payable converted into common stock in IPO			$15,410,110

Description_of_Business

Description of Business

3 Months Ended

12 Months Ended

Mar. 31, 2015

Dec. 31, 2014

Description of Business

Note 1. Description of Business

Capnia, Inc. (the “Company”) was incorporated in the State of Delaware on August 25, 1999, and is located in Redwood City, California. The Company develops products and therapeutics based on its proprietary technology for precision metering of gas flow.

Capnia, Inc. (the “Company”) was incorporated in the State of Delaware on August 25, 1999, and is located in Redwood City, California. The Company develops diagnostics and therapeutics based on its proprietary technology for precision metering of gas flow.

The Company’s first diagnostic product, CoSense®, aids in diagnosis of excessive hemolysis, a condition in which red blood cells degrade rapidly. When present in neonates with jaundice, hemolysis is a dangerous condition which can lead to long-term developmental disability. CoSense has 510(k) clearance for sale in the U.S. with a specific Indication for Use related to hemolysis issued, and has received CE Mark certification for sale in the European Union (“E.U.”). CoSense is commercially available in the U.S., with first commercial sales occurring in February 2015. In addition, the Company is applying its research and development efforts to additional diagnostic products based on its Sensalyze™ Technology Platform, a portfolio of proprietary methods and devices which enables CoSense and can be applied to detect a variety of analytes in exhaled breath. The Company has also obtained CE Mark certification in the E.U. for Serenz™, a therapeutic product candidate for the treatment of symptoms related to allergic rhinitis (“AR”).

The Company’s first diagnostic product, CoSense®, aids in diagnosis of excessive hemolysis, a condition in which red blood cells degrade rapidly. When present in neonates with jaundice, hemolysis is a dangerous condition which can lead to long-term developmental disability. CoSense received initial 510(k) clearance for sale in the U.S. in the fourth quarter of 2012, with a more specific Indication for Use related to hemolysis issued in the first quarter of 2014, and received CE Mark certification for sale in the European Union (“E.U.”) in the third quarter of 2013. The Company initiated commercialization of CoSense in October 2014 using its own sales efforts. In addition, the Company is applying its research and development efforts to additional diagnostic products based on its Sensalyze™ Technology Platform, a portfolio of proprietary methods and devices which enables CoSense and can be applied to detect a variety of analytes in exhaled breath.

The Company has also obtained CE Mark certification in the E.U. for Serenz™, a therapeutic product candidate for the treatment of symptoms related to allergic rhinitis (“AR”). The Company out licensed Serenz to Block Drug Company, a wholly-owned subsidiary of GlaxoSmithKline (“GSK”) in 2013, realizing revenue in the form of a non-refundable up-front payment of $3.0 million. In June 2014, the GSK agreement terminated and the licensed rights to Serenz were returned to the Company.

Initial Public Offering

On November 18, 2014, the Company completed its initial public offering (“IPO”), pursuant to which the Company issued 1,650,000 units (each unit consisting of one share of common stock, one Series A warrant and one Series B warrant) and received net proceeds of approximately $8.0 million, after deducting underwriting discounts and commissions and IPO related expenses. The following table summarizes the results of the Company’s IPO:

Transaction

Number of

Common

Proceeds

Units

Stock

Units Issued in IPO

1,650,000

10,708,500

Issuance of A & B Warrants (overallotment to underwriters)

—

18,975

Conversion of preferred Stock (one for one conversion ratio)

—

865,429

—

2010/2012 Convertible notes

—

3,165,887

—

2014 Convertible Notes

552,105

—

Totals

2,202,105

6,233,421

10,727,475

In addition to the above, upon the completion of the IPO, the 2009, 2010 and 2012 preferred stock warrants were converted into warrants to purchase 523,867 shares of the Company’s common stock (see Note 6).

As part of the IPO, the Company issued 2,449,605 Series A warrants to purchase 2,449,605 shares of the Company’s common stock. The Company also issued 2,449,605 Series B warrants to purchase an adjustable number of shares of the Company’s common stock (see Note 8).

Summary_of_Significant_Account

Summary of Significant Accounting Policies

3 Months Ended

12 Months Ended

Mar. 31, 2015

Dec. 31, 2014

Summary of Significant Accounting Policies

Note 3. Summary of Significant Accounting Policies

Note 2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the applicable rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. The condensed balance sheet at December 31, 2014 has been derived from the audited financial statements at that date, but does not include all disclosures, including notes, required by GAAP for complete financial statements.

The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the applicable rules and regulations of the Securities and Exchange Commission (“SEC”). The balance sheet at December 31, 2013 has been derived from the audited financial statements at that date.

The unaudited interim condensed financial statements have been prepared on the same basis as the audited financial statements and, in the opinion of management, reflect all adjustments of a normal recurring nature considered necessary to present fairly its financial position as of March 31, 2015 and results of its operations and comprehensive loss for the three months ended March 31, 2015 and 2014, and cash flows for the three months ended March 31, 2015 and 2014. The interim results are not necessarily indicative of the results for any future interim period or for the entire year. Certain prior period amounts have been reclassified to conform to current period presentation.

Significant Risks and Uncertainties

The accompanying condensed financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto for the year ended December 31, 2014 included in the Company’s Form 10-K.

The Company has experienced losses since its inception and, as of December 31, 2014, has an accumulated deficit of approximately $71.0 million and cash and cash equivalents of approximately $8.0 million. In 2013 the Company received payments totaling approximately $3.0 million pursuant to the license agreement with GSK pertaining to Serenz. This agreement terminated in June 2014, and the Company does not expect additional revenue to result from it. The Company plans to commercialize Serenz in the E.U. via a partnership or distributorship arrangements. In the U.S., the Company intends to determine the regulatory approval pathway for Serenz in dialogue with the FDA, and subsequently to seek partnership or distributorship arrangements for commercialization.

Use of Estimates

On November 18, 2014 the Company completed its IPO and received net proceeds of $8.0 million, after deducting underwriting discounts and commissions and IPO related expenses. On March 5, 2015 the Company received approximately $3.8M as a result of Series B warrant holders exercising warrants to purchase shares of the Company’s common stock.

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and reported amounts of expenses in the financial statements and accompanying notes. Actual results could differ from those estimates. Key estimates included in the financial statements include the valuation of deferred income tax assets and the valuation of debt and equity instruments and stock-based compensation.

The Company initiated its commercialization of CoSense starting in October of 2014, and will achieve profitability only if it can generate sufficient revenue from sales of the Company’s CoSense instruments and consumables, or from license fees, milestone payments, and research and development payments in connection with potential future strategic partnerships. Although management has been successful in raising capital in the past, most recently in April 2014, August 2014, October 2014, November 2014 and March 2015, there can be no assurance that the Company will be successful, or that any needed financing will be available in the future at terms acceptable to the Company.

Concentration of Credit Risk

Use of Estimates

Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents at two commercial banks that management believes are of high credit quality. Cash and cash equivalents deposited with these commercial banks exceeded the Federal Deposit Insurance Corporation insurable limit at March 31, 2015 and December 31, 2014. The Company expects this to continue.

Concentration of Credit Risk

Cash and Cash Equivalents

Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents at two commercial banks that management believes are of high credit quality. Cash and cash equivalents deposited with these commercial banks exceeded the Federal Deposit Insurance Corporation insurable limit at December 31, 2014 and 2013. The Company expects this to continue.

The Company considers all highly liquid investments, including its money market fund, purchased with an original maturity of three months or less to be cash equivalents. The Company’s cash and cash equivalents are held in institutions in the U.S. and include deposits in a money market fund which was unrestricted as to withdrawal or use. As of December 31, 2014 and March 31, 2015, the balance of the money market fund was $7.9 million and $6.5 million, respectively.

Segments

Inventory

The Company operates in one segment. Management uses one measurement of profitability and does not segregate its business for internal reporting, making operating decisions, and assessing financial performance. All long-lived assets are maintained in the United States of America.

Inventory as of December 31, 2014 consist of raw materials to be used in the manufacture of CoSense monitors and single-use nasal cannulas. Inventory is stated at the lower of cost or market under the first-in, first-out (FIFO) method. As of March 31, 2015, the Company’s inventory includes approximately $110 thousand of raw material, $61 thousand of work-in-process and $35 thousand in finished goods.

Cash and Cash Equivalents

Revenue Recognition

The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The Company’s cash and cash equivalents are held in institutions in the U.S. and include deposits in a money market fund which was unrestricted as to withdrawal or use.

The Company began recognizing sales of CoSense during the three months ended March 31, 2015. The Company recognizes revenue when all of the following criteria are met:

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of payments primarily related to insurance and short-term deposits. Prepaid expenses are initially recorded upon payment and are expensed as goods or services are received.

•

persuasive evidence of an arrangement exists;

Accounts Receivable

Accounts receivable as of December 31, 2013 consist of balances due from GSK pursuant to the license agreement executed in 2013. The Company did not record an allowance for doubtful accounts as this balance was deemed fully collectible.

•

the sales price is fixed or determinable;

Inventory

•

collection of the relevant receivable is probable at the time of sale; and

Property and Equipment, Net

Property and equipment are stated at cost net of accumulated depreciation and depreciated using the straight-line method over the estimated useful lives of the assets, generally between three and five years. Leasehold improvements are amortized on a straight-line basis over the lesser of their useful life or the term of the lease. Maintenance and repairs are charged to expense as incurred, and improvements are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operations in the period realized.

•

delivery has occurred or services have been rendered.

Convertible Instruments

For a majority of sales, where the Company delivers its product to hospitals or medical facilities, the Company recognizes revenue upon delivery, which represents satisfaction of the required revenue recognition criteria. The Company does not offer rights of return or price protection and it has no post-delivery obligations. The Company has a limited one-year warranty to most customers. Estimated warranty obligations are recorded at the time of sale and to date, warranty costs have been insignificant.

The Company evaluates and accounts for conversion options embedded in its convertible instruments in accordance with ASC 815 “Derivatives and Hedging.”

Research and Development

Research and development costs are charged to operations as incurred. Research and development costs consist primarily of salaries and benefits, consultant fees, prototype expenses, certain facility costs and other costs associated with clinical trials, net of reimbursed amounts.

ASC 815 generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not remeasured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument subject to the requirements of ASC 815. ASC 815 also provides an exception to this rule when the host instrument is deemed to be conventional (as that term is described in the implementation guidance to ASC 815).

Costs to acquire technologies to be used in research and development that have not reached technological feasibility and have no alternative future use are expensed to research and development costs when incurred.

The Company applies the accounting standards for derivatives and hedging and for distinguishing liabilities from equity when accounting for hybrid contracts that feature conversion options. The Company accounts for convertible debt instruments when the Company has determined that the embedded conversion options should not be bifurcated from their host instruments in accordance with ASC 470-20 “Debt with Conversion and Other Options.” The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt, using the effective interest method (see Note 6).

Convertible Preferred Stock Warrant Liability

Common Stock Purchase Warrants and Other Derivative Financial Instruments

The Company has issued freestanding warrants to purchase shares of its convertible preferred stock. Prior to the IPO, the Company classified the fair value of these warrants as liabilities on the balance sheet as they corresponded to the treatment of the preferred stock as temporary equity. The Company accounted for the warrants as derivative instruments. Changes in the fair value of the warrants were presented separately as other income (expense) in the Company’s statements of operations for each reporting period. The Company used the Monte Carlo simulation model to determine the fair values of the warrants. As a result, the valuation of this derivative instrument is subjective because the option-valuation model requires the input of highly subjective assumptions, including the expected stock price volatility and the probability of a future occurrence of a fundamental transaction. Changes in these assumptions can materially affect the fair value estimate and, such impacts can, in turn, result in material non-cash charges or credits, and related impacts on earnings or loss per share, in the statements of operations. At the time of the IPO, all of the warrants to purchase preferred stock were exchanged for warrants to purchase common stock, that met the conditions necessary for equity classification and are therefore no longer subject to adjustment to fair value.

The Company classifies common stock purchase warrants and other free standing derivative financial instruments as equity if the contracts (i) require physical settlement or net-share settlement or (ii) give the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The Company classifies any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the control of the Company), (ii) give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement), or (iii) contain reset provisions as either an asset or a liability. The Company assesses classification of its freestanding derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required. The Company determined that certain freestanding derivatives, which principally consist of Series A, Series B, and Series C warrants to purchase common stock, do not satisfy the criteria for classification as equity instruments due to the existence of certain cash settlement features that are not within the sole control of the Company or variable settlement provision that cause them to not be indexed to the Company’s own stock.

Series A Warrant Liability

Recent Accounting Pronouncements

The Company has issued Series A Warrants to purchase shares of its common stock. If, at any time while the Series A Warrants are outstanding, the Company enters into a “Fundamental Transaction” (as defined in the Series A Warrant Agreement), which includes, but is not limited to, a purchase offer, tender offer or exchange offer, a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or other scheme of arrangement), then each registered holder of outstanding Series A Warrants as at any time prior to the

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position or results of operations upon adoption.

consummation of the Fundamental Transaction, may elect and require the Company to purchase the Series A Warrants held by such person immediately prior to the consummation of such Fundamental Transaction by making a cash payment in an amount equal to the Black Scholes Value of the remaining unexercised portion of such registered holder’s Series A Warrants. Therefore, under ASC 815, the Company classified the fair value of these Series A Warrants as liabilities on the balance sheet due to this possibility that the Company may be obligated to settle the warrants in cash. As the warrants are publicly traded, the Company uses the closing price on the measurement date to determine the fair value of these warrants.

On June 10, 2014, the FASB issued ASU 2014-10, Elimination of Certain Financial Reporting Requirements, Including Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation. The pending content resulting from the issuance of ASU 2014-10 eliminates the definition of development stage entity, thereby removing the distinction between the development stage entities and other reporting entities. As a consequence, inception-to-date presentation and other incremental disclosure requirements in ASC Topic 915 for entities previously considered development stage entities are eliminated. For public business entities, the ASU’s elimination of the inception-to-date information and the other disclosures in Topic 915 is effective for annual reporting periods beginning after December 15, 2014, and interim periods therein. For other entities, this portion of the ASU is effective for annual reporting periods beginning after December 15, 2014, and interim reporting periods beginning after December 15, 2015. While the changes resulting from the issuance of ASU 2014-10 are not yet effective, early adoption of either the amendments to Topic 915 or Topic 810 is permitted for any annual or interim period for which a reporting entity’s financial statements have not yet been issued (public business entities) or made available for issuance (other entities.)

Series B Warrant Liability

The Company adopted ASU 2014-10 as of June 30, 2014, and therefore is no longer considered in the development stage. The Company continues to engage in research and development activities; however, the adoption of this ASU allows the Company to remove the inception to date information and all references to development stage in the accompanying financial statements.

The Company has issued Series B Warrants to purchase shares of its common stock. In the event that the market price of the Company’s common stock falls below $6.50 at any time between March 12, 2015 and February 12, 2016, the Series B Warrants will become exercisable on a cashless basis for a number of common shares that increases as the market price of the Company’s common stock decreases, and exercisable at a discount to the tracking price of the common stock at the time. The Company classified the fair value of these Series B Warrants as liabilities on the balance sheet in accordance with the guidance in ASC 815-40. The Company accounted for the warrants as derivative instruments, as the value is derived from the performance of an underlying entity, the Company’s common stock. The Company used the Monte Carlo simulation model to determine the fair value of the warrants. As a result, the valuation of this derivative instrument is subjective because the option-valuation model requires the input of highly subjective assumptions, including the expected stock price volatility. Changes in these assumptions can materially affect the fair value estimate and, such impacts can, in turn, result in material non-cash charges or credits, and related impacts on earnings or loss per share, in the statements of operations. The Company recorded changes in fair value of the Series B Warrants as a component of other income (expense).

The Company has considered all other recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements.

In addition to the Series B Warrants, the Company issued Series A Warrants in connection with its IPO, has other warrants issued prior to the IPO in connection with convertible debt and has other warrants classified as part of its permanent equity. Under ASC 815-40-35, the Company adopted a sequencing policy that reclassifies contracts from equity to assets or liabilities for those with the latest inception date first.

The Company will evaluate future issuance of securities as to reclassification as a liability under its sequencing policy of latest inception date first until either all of the Series B Warrants are settled or expire.

In accordance with the guidance under ASC 815-40-25, the Company has determined that it has a sufficient number of authorized and unissued shares, to settle all existing commitments as of December 31, 2014.

Convertible Preferred Stock

At the time of the IPO, all outstanding shares of preferred stock converted into common stock at a conversion rate of one to one, and were reclassified to permanent equity.

Revenue Recognition

The Company recognized revenue during the year ended December 31, 2013 pursuant to its license agreement with GSK. The revenue was recognized because there was persuasive evidence of an arrangement, the price was fixed or determinable, and collectability was reasonably assured. The up-front payment for revenue recognized in 2013 was received prior to December 31, 2013 and was nonrefundable. No revenue was recognized during the year ended December 31, 2014. The agreement was terminated in the second quarter of 2014, and the Company does not have any further monetary obligations with respect to this agreement.

Research and Development

Income Taxes

The Company accounts for income taxes using the asset and liability method. Under this method, deferred income tax assets and liabilities are recorded based on the estimated future tax effects of differences between the amounts at which assets and liabilities are recorded for financial reporting purposes and the amounts recorded for income tax purposes. Deferred income taxes are classified as current or non-current, based on the classifications of the related assets and liabilities giving rise to the temporary differences. A valuation allowance is provided against the Company’s deferred income tax assets when their realization is not reasonably assured.

The Company assesses all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position’s sustainability and is measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and the Company will determine whether (i) the factors underlying the sustainability assertion have changed and (ii) the amount of the recognized tax benefit is still appropriate. The recognition and measurement of tax benefits requires significant judgment. Judgments concerning the recognition and measurement of a tax benefit might change as new information becomes available.

Stock-Based Compensation

For stock options granted to employees, the Company recognizes compensation expense for all stock-based awards based on the estimated fair value on the date of grant. The value of the portion of the award that is ultimately expected to vest is recognized as expense ratably over the requisite service period. The fair value of stock options is determined using the Black-Scholes option pricing model. The determination of fair value for stock-based awards on the date of grant using an option pricing model requires management to make certain assumptions regarding a number of complex and subjective variables.

Stock-based compensation expense related to stock options granted to non-employees is recognized based on the fair value of the stock options, determined using the Black-Scholes option pricing model, as they are earned. The awards generally vest over the time period the Company expects to receive services from the non-employee.

Comprehensive Income (Loss)

Comprehensive income (loss) is defined as a change in equity of a business enterprise during a period, resulting from transactions from non-owner sources. There have been no items qualifying as other comprehensive income (loss) and, therefore, for all periods presented, the Company’s comprehensive income (loss) was the same as its reported net income (loss).

Net Income (Loss) per Share of Common Stock

Basic net income (loss) per common share is calculated by dividing the net income (loss) attributable to common stockholders by the weighted-average number of common stock outstanding during the period, without consideration for potentially dilutive securities. Diluted net income (loss) per share is computed by dividing the net income (loss) attributable to common stockholders by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net income (loss) per share calculation, convertible preferred stock, convertible promissory notes, stock options and stock warrants are considered to be potentially dilutive securities. Because the Company has reported a net loss for the years ended December 31, 2014 and 2013, diluted net loss per common share is the same as basic net loss per common share for those periods.

The following is a reconciliation of the number of shares used in the calculation of basic earnings per share and diluted earnings per share during the years ended December 31, 2014 and 2013:

Fiscal Year Ended

December 31,

2014

2013

(revised)

Net loss

(13,237,616

)

(3,707,243

)

Weighted-average shares used in computing basic and diluted net loss per common share

1,270,033

535,648

Basic and diluted net loss per common share

(10.42

)

(6.92

)

Effective as of the completion of the IPO, all of the Company’s preferred stock was converted to common stock.

The following potentially dilutive securities outstanding have been excluded from the computations of diluted weighted-average shares outstanding because such securities have an antidilutive impact due to losses reported (in common stock equivalent shares):

Fiscal Year Ended

December 31,

2014

2013

Convertible preferred stock

—

865,429

Warrants issued to 2010/2012 convertible note holders to purchase stock

523,867

Adjustable

Stock issuable upon conversion of convertible notes

—

Adjustable

Options to purchase common stock

1,072,011

239,606

Warrants issued in 2009 to purchase stock

9,259

Warrants issued to Underwriter to purchase common stock

82,500

—

Series A Warrants to purchase common stock

2,449,605

—

Series B Warrants to purchase common stock

Adjustable

—

Reverse Stock Split

The Company’s board of directors and stockholders approved an amendment to the Company’s amended and restated certificate of incorporation to effect a 1-for-12 reverse split of shares of the Company’s common stock and convertible preferred stock, and to change the total authorized number of common stock and convertible preferred stock, which amendment was filed with the Secretary of State of the State of Delaware on July 28, 2014. All issued and outstanding common stock, convertible preferred stock, options for common stock, warrants for preferred stock and per share amounts contained in the financial statements have been retroactively adjusted to reflect this reverse split for all periods presented. All authorized common stock and convertible preferred stock numbers contained in the financial statements have been adjusted to reflect the modifications effected pursuant to the July 28, 2014 amendment to the Company’s amended and restated certificate of incorporation.

Recent Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position or results of operations upon adoption.

The Company has considered all other recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements.

Revision_of_Prior_Year_Financi

Revision of Prior Year Financial Statements	3 Months Ended										12 Months Ended
Revision of Prior Year Financial Statements	Mar. 31, 2015										Dec. 31, 2014
Revision of Prior Year Financial Statements	Note 4. Revision of Prior Year Financial Statements										Note 3. Revision of Financial Statements
	It was determined during the preparation of the first quarter 2015 interim financial statements that the Series A Warrant Agreement contained provisions that if, at any time while the Series A Warrants are outstanding, the Company enters into a “Fundamental Transaction” (as defined in the Series A Warrant Agreement), which includes, but is not limited to, a purchase offer, tender offer or exchange offer, a stock or share purchase agreement or other business combination including, without limitation, a reorganization, recapitalization, spin-off or other scheme of arrangement), then each registered holder of outstanding Series A Warrants as at any time prior to the consummation of the Fundamental Transaction, may elect and require the Company to purchase the Series A Warrants held by such person immediately prior to the consummation of such Fundamental Transaction by making a cash payment in an amount equal to the Black Scholes Value of the remaining unexercised portion of such registered holder’s Series A Warrants. The Company determined that upon issuance in November 2014 the Series A Warrants should have been classified as a liability, with any changes in the fair value of the warrants between November 2014 and December 31, 2014 being recorded in other income (expense) in the statement of operations.										It was determined during the preparation of the first quarter 2015 interim financial statements that the Series A Warrant Agreement contained provisions that if, at any time while the Series A Warrants are outstanding, the Company enters into a “Fundamental Transaction” (as defined in the Series A Warrant Agreement), which includes, but is not limited to, a purchase offer, tender offer or exchange offer, a stock or share purchase agreement or other business combination including, without limitation, a reorganization, recapitalization, spin-off or other scheme of arrangement), then each registered holder of outstanding Series A Warrants as at any time prior to the consummation of the Fundamental Transaction, may elect and require the Company to purchase the Series A Warrants held by such person immediately prior to the consummation of such Fundamental Transaction by making a cash payment in an amount equal to the Black Scholes Value of the remaining unexercised portion of such registered holder’s Series A Warrants. The Company determined that upon issuance in November 2014 the Series A Warrants should have been classified as a liability, with any changes in the fair value of the warrants between November 2014 and December 31, 2014 being recorded in other income (expense) in the statement of operations.
	Management has evaluated the effect of the error and determined that it is immaterial to the Company’s financial position and results of operations for the year ended December 31, 2014 and, therefore, amendment of the previously filed annual report on Form 10-K is not considered necessary. However, if the adjustments to correct the cumulative errors had been recorded in the first quarter of 2015, we believe the impact would have been significant to the first quarter and would impact comparisons to prior periods. In accordance with guidelines issued in Staff Accounting Bulletin No. 108, we have recorded adjustments in the current year’s beginning additional paid in capital, long term liabilities and accumulated deficit accounts to correct this error. We have also revised in this current Form 10-Q filing, and plan to revise in future filings of our Form 10-K, the previously reported annual financial statements for 2014 on Form 10-K for these amounts.										Management has evaluated the effect of the error and determined that it is immaterial to the Company’s financial position and results of operations for the year ended December 31, 2014 and, therefore, amendment of the previously filed annual report on Form 10-K is not considered necessary. However, if the adjustments to correct the cumulative errors had been recorded in the first quarter of 2015, we believe the impact would have been significant to the first quarter and would impact comparisons to prior periods. In accordance with guidelines issued in Staff Accounting Bulletin No. 108, we have revised the financial statements included therein and recorded adjustments to additional paid in capital, long term liabilities, other expense, net loss and accumulated deficit accounts to correct this error.
	The following table sets forth the revised prior period balances reported in our our comparative financial statements as if adjustments had been made:
											The following table sets forth the revised balances reported in our comparative financial statements as if adjustments had been made:

	(in thousands except per share data)	Previously			Adjustment			Revised
	(in thousands except per share data)	reported			Adjustment			Revised			(in thousands except per share data)	Previously			Adjustment			Revised
	Balance sheet items at December 31, 2014:										(in thousands except per share data)	reported			Adjustment			Revised
	Current liabilities	$	1,290		$	—		$	1,290		Balance sheet items at December 31, 2014:
	Series A warrant liability		—			857			857		Current liabilities	$	1,290		$	—		$	1,290
	Series B warrant liability		17,439			—			17,439
											Series A warrant liability		—			857			857
	Total liabilities		18,729			857			19,586
	Additional paid-in capital		60,636			(1,494	)		59,141		Series B warrant liability		17,439			—			17,439
	Accumulated deficit		(70,975	)		637			(70,338	)
											Total liabilities		18,729			857			19,586
	Total stockholders’ deficit		(10,333	)		(857	)		(11,190	)
											Additional paid-in capital		60,636			(1,494	)		59,141
	Liabilities and stockholders’ deficit	$	8,396		$	—		$	8,396
											Accumulated deficit		(70,975	)		637			(70,338	)
	Statement of operations items for the year ended December 31, 2014
	Other income (expense)	$	(4,585	)	$	637		$	(3,949	)	Total stockholders’ deficit		(10,333	)		(857	)		(11,190	)

	Net loss	$	(13,875	)	$	637			(13,238	)	Liabilities and stockholders’ deficit	$	8,396		$	—		$	8,396

	Basic and diluted net loss per common share	$	(10.92	)	$	0.5			(10.42	)
											Statement of operations items for the year ended December 31, 2014

											Other income (expense)	$	(4,585	)	$	637		$	(3,949	)


											Net loss	$	(13,875	)	$	637			(13,238	)


											Basic and diluted net loss per common share	$	(10.92	)	$	0.5			(10.42	)

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	3 Months Ended																		12 Months Ended
Fair Value of Financial Instruments	Mar. 31, 2015																		Dec. 31, 2014
Fair Value of Financial Instruments	Note 5. Fair Value of Financial Instruments																		Note 4. Fair Value of Financial Instruments
	The carrying value of the Company’s cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued liabilities, approximate fair value due to the short-term nature of these items. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the line of credit approximates fair value.																		The carrying value of the Company’s cash, accounts receivable, prepaid expenses and other current assets, accounts payable, and accrued liabilities approximate fair value due to the short-term nature of these items. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the convertible promissory notes approximates their fair value.
	Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.																		Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.
	The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:
																			The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:

		• Level I		Unadjusted quoted prices in active markets for identical assets or liabilities;
																			• Level I	Unadjusted quoted prices in active markets for identical assets or liabilities;
		• Level II		Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and
																			• Level II	Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and
		• Level III		Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.
	The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.																		• Level III	Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.
	The following table sets forth the Company’s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):																		The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.
																			The following table sets forth the Company’s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy:

		Fair Value Measurements at December 31, 2014 (revised)
		Total			Level 1			Level 2			Level 3									Fair Value Measurements at December 31, 2013
	Assets																			Total		Level 1		Level 2		Level 3
	Money market fund	$	7,892		$	7,892		$	—		$	—							Assets
																			Money market fund	$	1,256,752	$	1,256,752	$	—	$	—
	Liabilities
	Series A warrant liability	$	857		$	857		$	—		$	—							Liabilities
	Series B warrant liability		17,439			—			—			17,439							Convertible preferred stock warrant liability	$	1,464,877	$	—	$	—	$	1,464,877

	Total common stock warrant liability	$	18,296		$	857		$	—		$	17,439
																				Fair Value Measurements at December 31, 2014 (revised)
																				Total		Level 1		Level 2		Level 3
																			Assets
		Fair Value Measurements at March 31, 2015																	Money market fund	$	7,892	$	7,892	$	—	$	—
		Total			Level 1			Level 2			Level 3
	Assets																		Liabilities
	Money market fund	$	6,472		$	6,472		$	—		$	—							Series A warrant liability	$	857	$	857	$	—	$	—
																			Series B warrant liability		17,439		—		—		17,439
	Liabilities
	Series A warrant liability		3,582			3,582			—			—							Total common stock warrant liability	$	18,296	$	857	$	—	$	17,349
	Series B warrant liability		14,180			—			—			14,180
	Series C warrant liability		2,549			—			—			2,549							For the fiscal year ended December 31, 2013, the fair value measurement of the convertible preferred stock warrant liability is based on significant inputs not observed in the market and thus represents a Level 3 measurement. The Company’s estimated fair value of the convertible preferred stock warrant liability is calculated using a Monte Carlo simulation and key assumptions including the probabilities of settlement scenarios, enterprise value, time to liquidity, risk-free interest rates, discount for lack of marketability and volatility (see Note 7). The estimates are based, in part, on subjective assumptions. Generally, increases or decreases in the fair value of the underlying convertible preferred stock would result in a directionally similar impact in the fair value measurement of the warrant liability. In connection with the completion of the Company’s IPO in November 2014, all of the outstanding warrants to purchase convertible preferred stock converted into warrants to purchase shares of common stock and were reclassified to permanent equity.

	Total common stock warrant liability	$	20,311		$	3,582		$	—		$	16,729							The fair value of the Series A Warrant liability is based on the closing price of the warrants using a NASDAQ trading price on November 18, 2014 and December 31, 2014, and therefore represent a Level 1 measurement. For the fiscal year ended December 31, 2014, the fair value measurement of the Series B warrant liability is based on significant inputs not observed in the market and thus represents a Level 3 measurement. The Company’s estimated fair value of the Series B warrant liability is calculated using a Monte Carlo simulation and key assumptions including the volatility, of the Company’s stock, expected dividend yield and risk-free interest rates (see Note 8). The estimates are based, in part, on subjective assumptions. Generally, increases or decreases in the trading price of the Company’s stock would result in a directionally opposite impact in the fair value measurement of the Series B warrant liability.
																			During the periods presented, the Company has not changed the manner in which it values liabilities that are measured at fair value using Level 3 inputs. The Company recognizes transfers between levels of the fair value hierarchy as of the end of the reporting period. There were no transfers within the hierarchy during the periods presented.
	The Series A Warrants are a registered security that trades on the open market. The fair value of the Series A Warrant liability is based on the publicly quoted trading price of the warrants which are listed on and obtained from NASDAQ. Accordingly, the Series A Warrants are a Level 1 measurement. The fair value measurement of the Series B and Series C Warrants are based on significant inputs that are unobservable and thus represents a Level 3 measurement. The Company’s estimated fair value of the Series B Warrant liability is calculated using a Monte Carlo simulation. Key assumptions include the volatility of the Company’s stock, the Company’s stock price, expected dividend yield and risk-free interest rates (see Note 6). The Company’s estimated fair value of the Series C Warrant liability is calculated using the Black-Scholes valuation model. Key assumptions include the volatility of the Company’s stock, the Company’s stock price, expected dividend yield and risk-free interest rates (see Note 6). The Level 3 estimates are based, in part, on subjective assumptions.
	During the periods presented, the Company has not changed the manner in which it values liabilities that are measured at fair value using Level 3 inputs. The Company recognizes transfers between levels of the fair value hierarchy as of the end of the reporting period. There were no transfers within the hierarchy during the periods presented.

	The following table sets forth a summary of the changes in the fair value of the Company’s Level 1 and Level 3 financial instruments, which are treated as liabilities, as follows:


		Series A Warrant						Series B Warrant						Series C Warrant
		Number of			Liability			Number of			Liability			Number of		Liability
		Warrants			Liability			Warrants			Liability			Warrants		Liability
					(in thousands)						(in thousands)					(in thousands)
	Balance at December 31, 2014 (revised)		2,449,605		$	857			2,449,605		$	17,439			—	$	—
	Change in value of Series A Warrants		—			2,767			—			—			—		—
	De-recognition of Series A Warrant liability upon exercise		(24,000	)		(42	)		—			—			—		—
	De-recognition of Series B Warrant liability upon cash exercise of 589,510 warrants in Private Transaction (589,510 shares issued)		—			—			(589,510	)		(6,430	)		—		—
	De-recognition of Series B Warrant liability for other cash exercises of 29,097 warrants (29,097 shares issued)		—			—			(29,097	)		(317	)		—		—
	De-recognition of Series B Warrant liability upon cashless exercise of 52,255 warrants (21,186 shares issued)		—			—			(52,255	)		(418	)		—		—
	De-recognition of Series B Warrant liability upon contribution of 468 warrants back to the Company		—			—			(468	)		(3	)		—		—
	Change in value of Series B Warrants		—			—			—			3,909			—		—
	Record Series C Warrant Liability		—			—			—			—			589,510		3,050
	Change in value of Series C Warrants		—			—			—			—			—		(501	)

	Balance at March 31, 2015		2,425,605		$	3,582			1,778,275		$	14,180			589,510	$	2,549

Property_and_Equipment_Net

Property and Equipment, Net	12 Months Ended
Property and Equipment, Net	Dec. 31, 2014
Property and Equipment, Net	Note 5. Property and Equipment, Net
	Property and equipment consisted of the following:


		December 31,			December 31,
		2014			2013
	Furniture and fixtures	$	170,811		$	180,238
	Computer hardware		27,555			27,555
	Leasehold improvements		4,075			10,726

		$	202,441		$	218,519
	Less accumulated depreciation and amortization		(144,834	)		(155,352	)

	Total	$	57,607		$	63,167

	Depreciation expense was $42,114 and $28,516 for the fiscal years ended December 31, 2013 and December 31, 2014, respectively.

Related_Party_Convertible_Prom

Related Party Convertible Promissory Notes	12 Months Ended
Related Party Convertible Promissory Notes	Dec. 31, 2014
Related Party Convertible Promissory Notes	Note 6. Related Party Convertible Promissory Notes
	2010/2012 Convertible Promissory Notes
	In 2010 and 2012 the Company entered into convertible promissory notes with various investors for a total principal amount of $10,200,413. These notes were collateralized by substantially all of the assets of the Company and bore interest at a compounded interest rate of 12% per annum. As of the completion of the IPO on November 18, 2014, the Company had $15,410,110 in aggregate principal amount and accrued interest outstanding under the 2010/2012 convertible promissory notes, which automatically converted into 3,165,887 shares of common stock in conjunction with the IPO based on a conversion price of $4.87 per share of common stock which represented the contractual conversion price of 75% of the price of common stock issued in the IPO. The Company incurred $2,860,267 and $1,416,554 of interest expense related to these notes in the years ended December 31, 2013 and December 31, 2014, respectively.

	In connection with the 2010/2012 convertible promissory notes the Company issued warrants for the purchase of preferred stock (see Note 7).
	2014 Convertible Promissory Notes
	In April 2014, the Company entered into convertible promissory notes with various investors for a total principal amount of $1,747,681. These notes bore interest at the rate of 2% per annum in the event that the note is automatically converted into units, equal to one share of common stock and a warrant to purchase one share of common stock, upon the Company’s IPO, prior to the maturity date of September 30, 2015. These notes automatically converted to units upon completion of the Company’s IPO based on a conversion price of $4.55 per unit, which represented the contractual conversion price of 70% of the price per unit issued in the IPO.
	In connection with the April 2014 convertible notes, the Company issued a warrant for the purchase of preferred stock. The number of shares for which the warrant may be exercised is to be determined by dividing an amount equal to 25% of the unpaid principal by the exercise price prior to the expiration of this warrant. The exercise price for the warrant is 75% of the price per share of the next financing securities issued in the next financing or $16.20 per share if converted into the Series C preferred stock. The warrants are exercisable: (1) after the earlier of (a) the closing date of a next financing that occurs prior to the Company’s consummation of the IPO or (b) the note maturity date and (2) prior to the expiration of this warrant on the earlier of 10 years or the date of a qualified IPO. The estimated fair value of the warrants at issuance was determined to be $600,148, which was recorded as a debt discount and amortized using the effective interest method over the term of the convertible notes. The Company estimated the fair value of its preferred stock warrant liability at issuance utilizing a Monte Carlo simulation based on expected volatility range of 35%-60%, expected time to liquidity event of 1.50-5 years and risk-free interest rate range of 0.2-2.6%. The Company determined that these warrants met the conditions necessary for liability classification (see Note 7).
	After allocating $600,148 to the warrants issued in connection with the April 2014 convertible notes as discussed above, the Company determined the intrinsic value of the beneficial conversion feature to be $1,347,406, which was recorded as a debt discount to the convertible notes and within additional paid-in capital. The debt discount was amortized using the effective interest rate method over the term of the convertible notes. The discount to convertible notes for the intrinsic value of the beneficial conversion feature embedded in debt instruments is based upon the differences between the fair value of the underlying preferred stock at the commitment date of the note transaction and the effective conversion price embedded in the note.
	In August 2014, the Company entered into convertible promissory notes with various investors for a total principal amount of $249,693. These notes bore interest at the rate of 2% per annum in the event that the note is automatically converted into units, equal to one share of common stock and a warrant to purchase one share of common stock, upon the Company’s IPO, prior to the maturity date of September 30, 2015. These notes automatically converted to units upon completion of the Company’s IPO based on a conversion price of $4.55 per unit, which represented the contractual conversion price of 70% of the price per unit issued in the IPO.
	In connection with the August 2014 convertible notes, the Company issued a warrant for the purchase of preferred stock. The number of shares for which the warrant may be exercised is to be determined by dividing an amount equal to 25% of the unpaid principal by the exercise price prior to the expiration of this warrant. The exercise price for the warrant is 75% of the price per share of the next financing securities issued in the next financing or $16.20 per share if converted into Series C preferred stock. The warrants are exercisable: (1) after the earlier of (a) the closing date of a next financing that occurs prior to the Company’s consummation of the IPO or (b) the note maturity date and (2) prior to the expiration of this warrant on the earlier of 10 years or the date of a qualified IPO. The estimated fair value of the warrants at issuance was determined to be $113,295, which was recorded as a debt discount and amortized using the effective interest method over the term of the convertible notes. The Company estimated the fair value of its preferred stock warrant liability at issuance utilizing a Monte Carlo simulation based on expected volatility range of 35%-60%, expected time to liquidity event of 1.25-5 years and risk-free interest rate of 0.2-2.26%. The Company determined that these warrants met the conditions necessary for liability classification (see Note 7).
	After allocating $113,295 to the warrants issued in connection with the August 2014 convertible notes as discussed above, the Company determined the intrinsic value of the beneficial conversion feature to be $136,705, which was recorded as a debt discount to the convertible notes and within additional paid-in capital. The debt discount was amortized using the effective interest rate method over the term of the convertible notes. The discount to convertible notes for the intrinsic value of the beneficial conversion feature embedded in debt instruments is based upon the differences between the fair value of the underlying preferred stock at the commitment date of the note transaction and the effective conversion price embedded in the note.
	In October 2014, the Company entered into convertible promissory notes with various investors for a total principal amount of $493,407. These notes bore interest at the rate of 2% per annum in the event that the note is automatically converted into units, equal to one share of common stock and a warrant to purchase one share of common stock, upon the Company’s IPO, prior to the maturity date of September 30, 2015. These notes automatically converted to units upon completion of the Company’s IPO based on a conversion price of $4.55 per unit, which represented the contractual conversion price of 70% of the price per unit issued in the IPO.
	In connection with the October 2014 convertible notes, the Company issued a warrant for the purchase of preferred stock. The number of shares for which the warrant may be exercised is to be determined by dividing an amount equal to 25% of the unpaid principal by the exercise price prior to the expiration of this warrant. The exercise price for the warrant is 75% of the price per share of the next financing securities issued in the next financing or $16.20 per share if converted into the Series C preferred stock. The warrants are exercisable: (1) after the earlier of (a) the closing date of a next financing that occurs prior to the Company’s consummation of the IPO or (b) the note maturity date and (2) prior to the expiration of this warrant on the earlier of 10 years or the date of a qualified IPO. The estimated fair value of the warrants at issuance was determined to be $253,535, which was recorded as a debt discount and amortized using the effective interest method over the term of the convertible notes. The Company estimated the fair value of its preferred stock warrant liability at issuance utilizing a Monte Carlo simulation based on expected volatility range of 35%-60%, expected time to liquidity of event of 1.0 years-5 years and risk-free interest rate of 0.2-2.26%. The Company determined that these warrants met the conditions necessary for liability classification. (See Note 7).
	After allocating $253,535 to the warrants issued in connection with the October 2014 convertible notes as discussed above, the Company determined the intrinsic value of the beneficial conversion feature to be $239,872, which was recorded as a debt discount to the convertible notes and within additional paid-in capital. The debt discount was amortized using the effective interest rate method over the term of the convertible notes. The discount to convertible notes for the intrinsic value of the beneficial conversion feature embedded in debt instruments is based upon the differences between the fair value of the underlying preferred stock at the commitment date of the note transaction and the effective conversion price embedded in the note.

	In relation to the April, August and October 2014 convertible notes payable, the Company recognized interest expense through November 18, 2014 of $21,348. The Company recorded interest expense in connection with the amortization of the debt discount through November 18, 2014 of $835,509. In addition, the Company recorded interest expense of $1,855,452 related to the write-off of the unamortized portion of the debt discount upon the conversion of the notes upon the date of the IPO.
	Prior to the completion of the IPO on November 18, 2014, the Company had $2,512,119 in aggregate principal amount and accrued interest outstanding under the April, August and October 2014 convertible promissory notes. The 2014 convertible promissory notes automatically converted into units of common stock and warrants issued in the IPO. Based on the IPO price of $6.50 per unit, the April, August and October 2014 convertible promissory notes automatically converted into 552,105 units (which consisted of 552,105 shares of common stock, Series A warrants to purchase 552,105 shares of common stock, and Series B warrants to purchase 552,105 shares of common stock).

Convertible_Preferred_Stock_Wa

Convertible Preferred Stock Warrants

12 Months Ended

Dec. 31, 2014

Convertible Preferred Stock Warrants

Note 7. Convertible Preferred Stock Warrants

In 2010 and 2012, in conjunction with the related party convertible note financings, the Company issued preferred stock warrants. The number of shares for which the warrant may be exercised is to be determined by dividing an amount equal to 25% of the unpaid principal by (a) 75% of the price per share of the equity securities issued in the next round of equity financing under certain conditions or (b) if converting into Series C preferred stock, $16.20 per share. The exercise price for the warrant is 75% of the price per share of equity securities issued in such financing or $16.20 per share if converted into the Series C preferred stock. The warrants are immediately exercisable and will expire 10 years from the original issuance date. The Company re-measured the associated fair value of the convertible preferred stock warrant liability at each reporting period.

As of December 31, 2013, the Company used a Monte Carlo simulation to calculate the fair value of its convertible preferred stock warrant liability using the following inputs:

December 31,

2013

Volatility

38% - 47%

Expected Term (years)

0.75 - 2.00

Expected dividend yield

0.00%

Risk-free rate

0.12% - 0.38%

In addition to the assumptions above, the Company’s estimated fair value of the convertible preferred stock warrant liability is calculated using other key assumptions including the probability and value of the next equity financing, enterprise value, and discount for lack of marketability. Management, with the assistance of an independent valuation firm, makes these subjective determinations based on available current information; however, as such information changes, so might management’s determinations and such changes could have a material impact of future operating results.

The Company changed the methodology described above to calculate the fair value of its preferred stock warrant upon the IPO, as all of preferred stock warrants converted into warrants to purchase shares of common stock and the IPO was completed. The Company used a Black Scholes model to calculate the value of these warrants on November 18, 2014 using the following inputs:

November 18,

2014

Volatility

61% -71.2%

Contractual Term (years)

4.5 -7.5

Expected dividend yield

0.00%

Risk-free rate

1.50% -2.09%

Stock Price

$4.00

Exercise Price

$4.87 - $21.60

As of December 31, 2013 and November 18, 2014 (IPO date), outstanding convertible preferred stock warrants consisted of:

Issuance date

Contractual

Exercise price per

Number of shares

Fair Value at

Term

underlying

December 31, 2013

November 18, 2014

warrant

Jan-09

10 years

21.6

9,259

42,444

2,911

2010/2012

10 years

Adjustable

1,422,433

1,217,808

Total

1,464,877

1,220,719

The decrease in the fair value of the 2009 and 2010/2012 warrants between 12/31/2013 and the IPO date of $244,151 was recorded as other income during the year ended December 31, 2014. In connection with the completion of the Company’s IPO, the 2009 and 2010/2012 outstanding warrants to purchase convertible preferred stock converted into warrants to purchase 523,867 shares of the Company’s common stock with an exercise price of $4.87 and are no longer subject to adjustment to fair value as they were reclassified to permanent equity upon conversion.

In addition to the above, the preferred stock warrants that were issued in connection with the Company’s 2014 convertible promissory notes expired upon the IPO. The fair value of the preferred stock warrant liability related to the 2014 notes was derecognized as a liability and accordingly the Company recorded a gain of $967,234 as other income during the year ended December 31, 2014.

As of December 31, 2013 all warrants issued by the Company prior to the IPO were issued to related parties consisting of investors and the Chairman of the Board.

Upon the IPO, the January 2009 warrants became exercisable for 9,259 of the Company’s common stock, with an exercise price of $21.60.

Warrant_Liabilities

Warrant Liabilities

3 Months Ended

12 Months Ended

Mar. 31, 2015

Dec. 31, 2014

Warrant Liabilities

Note 6. Warrant Liabilities

Note 8. Series A Warrants and Series B Warrants

Warrants terms

Series A Warrants

The Company has issued Series A Warrants, Series B Warrants and Series C Warrants (the “Warrants”).

The Company has issued Series A warrants to purchase shares of its common stock at an exercise price of $6.50 per share. The total proceeds from the issuance of the Series A warrants in the IPO was $9,488.

The Company’s Series A, Series B, and Series C Warrants contain standard anti-dilution provisions for stock dividends, stock splits, subdivisions, combinations and similar types of recapitalization events. They also contain a cashless exercise feature that provides for their net share settlement at the option of the holder in the event that there is no effective registration statement covering the continuous offer and sale of the warrants and underlying shares. The Company is required to comply with certain requirement to cause or maintain the effectiveness of a registration statement for the offer and sale of these securities. The Warrant contracts further provide for the payment of liquidated damages at an amount per month equal to 1% of the aggregate VWAP of the shares into which each Warrant is convertible into in the event that the Company is unable to maintain the effectiveness of a registration statement as described herein. The Company evaluated the registration payment arrangement stipulated in the terms of these securities and determined that it is probable that the Company will maintain an effective registration statement and has therefore not allocated any portion of the IPO or Private Transaction proceeds to the registration payment arrangement. The Warrants also contain a fundamental transactions provision that permits their settlement in cash at fair value at the option of the holder upon the occurrence of a change in control. Such change in control events include tender offers or hostile takeovers, which are not within the sole control of the Company as the issuer of these warrants. Accordingly, the warrants are considered to have a cash settlement feature that precludes their classification as equity instruments. Settlement at fair value upon the occurrence of a fundamental transaction would be computed using the Black Scholes Option Pricing Model.

The Series A warrants are exercisable prior to the expiration of the five-year term on November 12, 2019. If, at any time while the Series A Warrants are outstanding, the Company enters into a “Fundamental Transaction” (as defined in the Series A Warrant Agreement), which includes, but is not limited to, a purchase offer, tender offer or exchange offer, a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or other scheme of arrangement), then each registered holder of outstanding Series A Warrants as at any time prior to the consummation of the Fundamental Transaction, may elect and require the Company to purchase the Series A Warrants held by such person immediately prior to the consummation of such Fundamental Transaction by making a cash payment in an amount equal to the Black Scholes Value of the remaining unexercised portion of such registered holder’s Series A Warrants. Therefore, under ASC 815, the Company classified the fair value of these Series A warrants as liabilities on the balance sheet due to this possibility that the Company may be obligated to settle the warrants in cash. Upon the completion of the IPO, the Series A warrants started trading on the NASDAQ under the symbol CAPNW. As the warrants are publicly traded, the Company uses the closing price on the measurement date to determine the fair value of these warrants.

Accounting Treatment

As of November 18, 2014 and December 31, 2014, the outstanding Series A Warrants and fair market values were:

The Company accounts for the Warrants in accordance with the guidance in ASC 815 Derivatives and Hedging. As indicated, above the Company may be obligated to settle warrants in cash in the case of a Fundamental Transaction.

Additionally, the terms of the Series B Warrants do not explicitly limit the potential number of shares, thereby the exercise of the Series B Warrants could result in the Company’s obligation to deliver a potentially unlimited number of shares upon settlement. As such, share settlement is not considered to be within the control of the Company.

The Company classified the Series A, Series B, and C Warrants as liabilities at their fair value and will re-measure the warrants at each balance sheet date until they are exercised or expire. Any change in the fair value is recognized as other income (expense) in the Company’s statement of operations.

Issuance date

Contractual

Exercise price per

Number of

Shares underlying

Fair Value at

Under ASC 815-40-35, the Company adopted a sequencing policy that reclassifies contracts, with the exception of stock options, from equity to assets or liabilities for those with the latest inception date first. Future issuance of securities will be evaluated as to reclassification as a liability under our sequencing policy of latest inception date first until either all of the Series B warrants are settled or expire.

Term

warrants

November 18, 2014

December 31, 2014

In accordance with the guidance under ASC 815-40-25, we have evaluated that we have a sufficient number of authorized and unissued shares as March 31, 2015, to settle all existing commitments.

Nov-14

5 years

6.5

2,449,605

1,494,259

857,362

Series A Warrants

The decrease in the fair value of the Series A Warrants between the IPO date and 12/31/2014 of $636,897 was recognized on a revised basis as other income during the year ended December 31, 2014.

The Company has issued 2,449,605 Series A Warrants to purchase shares of its Common Stock at an exercise price of $6.50 per share in connection with the IPO unit offering described in Note 2. The Series A Warrants are exercisable at any time prior to the expiration of the five-year term on November 12, 2019. Upon the completion of the IPO, the Series A warrants started trading on the NASDAQ under the symbol CAPNW. As the warrants are publicly traded, the Company uses the closing price on the measurement date to determine the fair value of these warrants.

Upon completion of the Company’s IPO on November 18, 2014, the 2014 convertible promissory notes automatically converted into 552,105 units (which consisted of 552,105 shares of common stock, Series A Warrants to purchase 552,105 shares of common stock and Series B warrants to purchase 552,105 shares of common stock). In addition, the Company issued 1,897,500 Series A warrants in connection with its IPO.

During the quarter ended March 31, 2015, a total of 24,000 Series A Warrants were exercised. As of March 31, 2015, the fair value of the remaining 2,425,605 outstanding Series A Warrants was approximately $3.6 million. The increase in the fair value of the Series A warrants of $2.8 million during the quarter ended March 31, 2015 was recorded as other expense in the statement of operations.

Series B Warrants

The Company has issued 2,449,605 Series B Warrants to purchase shares of its Common Stock. In the event that the market price of the Company’s common stock falls below $6.50 at any time between March 12, 2015 and February 12, 2016, the Series B Warrants will become exercisable on a cashless basis for a number of common shares that increases as the market price of the Company’s common stock decreases, and exercisable at a discount to the tracking price of the common stock at the time. The result is an inverse relationship between the fair value of the shares and the number of shares issuable.

As December 31, 2014, and March 31, 2015 the Company used a Monte Carlo simulation to calculate the fair value of its Series B Warrant liability. This model is dependent upon several variables such as the warrant’s term, exercise price, current stock price, risk-free interest rate estimated over the contractual term, estimated volatility of our stock over the term of the warrant and the estimated market price of our stock during the cashless exercise period. The risk-free rate is based on U.S. Treasury securities with similar maturities as the expected terms of the warrants. The volatility is estimated based on blending the volatility rates for a number of similar publicly-traded companies. The Company used the following inputs:

The Company accounts for the Series B Warrants in accordance with the guidance in ASC 815-40. The terms of the Series B Warrants do not explicitly limit the potential number of shares, thereby the exercise of the B warrants could result in the Company’s obligation to deliver a potentially unlimited number of shares upon settlement. As such, share settlement is not considered to be within the control of the Company and as provided under ASC 815-40, the warrants do not meet the criteria for equity classification and are recorded as a liability. Accordingly, the Company classified the Series B Warrants as liabilities at their fair value at the date of the IPO and will re-measure the warrants at each balance sheet date until they are exercised or expire. Any change in the fair value is recognized as other income (expense) in the Company’s statement of operations.

As of November 18, 2014 and December 31, 2014, the Company used a Monte Carlo simulation to calculate the fair value of its Series B Warrant liability. This model is dependent upon several variables such as the warrant’s term, exercise price, current stock price, risk-free interest rate estimated over the contractual term, estimated volatility of our stock over the term of warrant and the estimated market price of our stock during the cashless exercise period. The risk-free rate is based on U.S. Treasury securities with similar maturities as the expected terms of the warrants. The volatility is estimated based on blending the volatility rates for a number of similar publicly-traded companies. The Company used the following inputs:

December 31,

March 31,

2014

2015

November 18,

December 31,

Volatility

86.6

100

2014

Expected Term (years)

1.1

0.87

Volatility

Expected dividend yield

Expected Term (years)

1.25

1.1

Risk-free rate

0.26

Expected dividend yield

In addition to the assumptions above, the Company’s estimated fair value of the Series B Warrant liability is calculated using other key assumptions. Management, with the assistance of an independent valuation firm, makes these subjective determinations based on available current information; however, as such information changes, so might management’s determinations and such changes could have a material impact of future operating results.

Risk-free rate

0.2

0.26

As of December 31, 2014 and March 31, 2015 the outstanding Series B Warrants and fair market values were:

In addition to the assumptions above, the Company’s estimated fair value of the Series B warrant liability is calculated using other key assumptions. Management, with the assistance of an independent valuation firm, makes these subjective determinations based on available current information; however, as such information changes, so might management’s determinations and such changes could have a material impact of future operating results.

As of November 18, 2014 and December 31, 2014, the outstanding Series B Warrants and fair market values were:

Issuance date

Contractual

Exercise price

Number of

Fair Value at

Number of

Fair Value at

Term

per share

Underlying

Warrants at

December 31, 2014

Warrants at

March 31, 2015

Issuance date

Contractual

Exercise price per

Number of

Shares underlying

Fair Value at

warrants

December 31, 2014

(in thousands)

March 31, 2015

(in thousands)

Term

warrants

November 18, 2014

December 31, 2014

November 2014

15 months

6.5

Adjustable

2,449,605

17,439

1,778,275

14,180

Nov-14

15 months

Adjustable

2,449,605

Adjustable

11,649,106

17,438,731

On March 5, 2015, certain Series B Warrant holders exercised a total of 589,510 Series B Warrants. Immediately prior to the exercise, the Company re-measured the fair value of the warrants, which was approximately $6.7 million. The increase in the fair value of $2.3 million between December 31, 2014 and the date of exercise was recorded as other expense in the statement of operations. During the three months ended March 31, 2015 there were cashless exercises of 52,255 Series B Warrants. There were 1,778,275 Series B warrants that remained outstanding as of March 31, 2015. The increase in fair value of these remaining warrants was $1.5 million during the quarter ended March 31, 2015, which was recorded as other expense in the statement of operations.

The increase in the fair value of the Series B Warrants between the IPO date and 12/31/2014 of $5,789,625 was recognized as an other expense during the year ended December 31, 2014.

Series C Warrants

In addition to the Series B warrants, the Company issued Series A Warrants in connection with its IPO, has other warrants issued prior to the IPO in connection with convertible debt and has other warrants classified as part of its permanent equity. Under ASC 815-40-35, the Company has adopted a sequencing policy that reclassifies contracts from equity to assets or liabilities for those with the latest inception date first.

On March 5, 2015, the Company entered into separate agreements with certain Series B Warrant holders, who agreed to exercise their Series B Warrants to purchase an aggregate of 589,510 shares of the Company’s common stock at an exercise price of $6.50 per share, resulting in gross proceeds to the Company of approximately $3.8 million. In connection with this exercise of the Series B Warrants, the Company issued to each investor who exercised Series B Warrants, new Series C Warrants for the number of shares of the Company’s Common Stock underlying the Series B Warrants that were exercised. Each Series C Warrant is exercisable at $6.25 per share and will expire on March 5, 2020. The new Series C Warrants are exercisable into 589,510 shares of the Company’s Common Stock. On the date of issuance, the fair value of the Series C Warrants determined using the Black-Scholes valuation model was approximately $3.0 million. The Series C Warrants were treated as an inducement to enter into the transaction, and as such the $3.0 million fair value of the Series C Warrants was recorded as other expense in the statement of operations. As of March 31, 2015, the fair value of the Series C Warrants was determined to be $2.5 million. The decline in the fair value of the warrants of $0.5 million between the issuance date and March 31, 2015 was recorded as other income in the statement of operations.

In accordance with the guidance under ASC 815-40-25, the Company has evaluated that it has a sufficient number of authorized and unissued shares, to settle all existing commitments as of December 31, 2014.

The Company has calculated the fair value of the Series C warrants using a Black-Scholes pricing model, which requires the input of highly subjective assumptions including the expected stock price volatility. The Company used the following inputs:

March 4,

March 31,

2015

Volatility

Expected Term (years)

4.93

Expected dividend yield

Risk-free rate

1.37

1.35

Credit_Facility

Credit Facility	3 Months Ended	12 Months Ended
Credit Facility	Mar. 31, 2015	Dec. 31, 2014
Credit Facility	Note 7. Credit Facility	Note 9. Line of Credit
	On September 29, 2014, the Company established a line of credit in the amount of up to $0.1 million. The line of credit bears a fixed interest rate of 6.0% per annum simple interest. The line of credit has a two-year repayment term, with prepayment at the Company’s option with no penalty. The line of credit shall be payable out of cash received in the Company’s accounts receivable following their commencement of commercial sales.
	In October, 2014, the Company drew down the full amount of $0.1 million provided for by the line of credit. During the three months ended March 31, 2015, the Company repaid the outstanding amounts borrowed under the line of credit.	On September 29, 2014, the Company established a line of credit in the amount of up to $0.1 million. The line of credit bears a fixed interest rate of 6.0% per annum simple interest. The line of credit has a two-year repayment term, with prepayment at the Company’s option with no penalty. The line of credit shall be payable out of cash received in the Company’s accounts receivable following the commencement of commercial sales.

		In October, 2014, the Company drew down the full amount of $0.1 million provided for by the line of credit.

Commitments

Commitments	3 Months Ended	12 Months Ended
Commitments	Mar. 31, 2015	Dec. 31, 2014
Commitments	Note 8. Commitments and Contingencies	Note 10. Commitments
	Facility Leases
	The Company leases its headquarters facility under a non-cancelable operating lease agreement which was set to expire in May 2015. As of December 31, 2014, the Company’s future minimum commitments under non-cancelable operating lease were approximately $18,000. On February 2, 2015, the Company signed an amendment to its lease agreement, extending the lease through June 2018. The amendment provides for monthly lease payments of $22,000 beginning in June 2015, with modest increases in the following two years.	Facility Leases
	Rent expense was $57,000 and $62,000 during the three months ended March 31, 2014 and 2015, respectively.
	Contingencies	The Company leases its headquarters facility under a non-cancelable operating lease agreement set to expire the end of May 2015. The Company previously leased two other facilities under non-cancelable operating lease agreements that expired in January 2014 and May 2014, respectively. Rent expense was $304,000 and $230,000 during the fiscal years ended December 31, 2013 and December 31, 2014, respectively.
	In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.
	In 2010 the Company entered into an asset purchase agreement with BioMedical Drug Development, Inc. Pursuant to the agreement, the Company made a payment of $150,000 for the acquisition of intellectual property which the Company used to develop its product, CoSense. As part of the terms of the agreement, the Company is contingently committed to make development and sales-related milestone payments of up to $200,000 under certain circumstances, as well as single-digit-percentage royalties relating to potential planned product sales of CoSense. The amount, timing and likelihood of these payments are unknown, as they are dependent on the occurrence of future events that may or may not occur. In 2013 and during the nine months ended September 30, 2014, the Company made no payments and incurred no liabilities in connection with the agreement, and there are no outstanding payments due as of December 31, 2014 and as of March 31, 2015.	As of December 31, 2014, the Company’s future minimum commitment under the non-cancelable operating lease is approximately $18,000.

		Product Development Agreement

		In 2010 the Company entered into an asset purchase agreement with BioMedical Drug Development, Inc. Pursuant to the agreement, the Company made a payment of $150,000 for the acquisition of intellectual property which the Company used to develop its product, CoSense. As part of the terms of the agreement, the Company is contingently committed to make development and sales-related milestone payments of up to $200,000 under certain circumstances, as well as single-digit-percentage royalties relating to potential planned product sales of CoSense. The amount, timing and likelihood of these payments are unknown, as they are dependent on the occurrence of future events that may or may not occur. During the fiscal years ended December 31, 2013 and December 31, 2014, the Company made no payments and incurred no liabilities in connection with the agreement, and there are no outstanding payments due as of December 31, 2013 and December 31, 2014.

Stockholders_Deficit

Stockholders' Deficit	3 Months Ended										12 Months Ended
Stockholders' Deficit	Mar. 31, 2015										Dec. 31, 2014
Stockholders' Deficit	Note 9. Stockholders’ Deficit										Note 11. Capital Stock
	Stock Option Plan
	The Company has adopted the 1999 Incentive Stock Plan, the 2010 Equity Incentive Plan, and the 2014 Equity Incentive Plan (together, the Plans). The 1999 Incentive Stock Plan expired in 2009, and the 2010 Equity Incentive Plan has been closed to new issuances. Therefore, the Company may issue options to purchase shares of common stock to employees, directors, and consultants only under the 2014 Equity Incentive Plan. Options granted under the 2014 Plan may be incentive stock options (“ISOs”) or nonqualified stock options (“NSOs”). ISOs may be granted only to Company employees and directors. NSOs may be granted to employees, directors, advisors, and consultants. The Board of Directors has the authority to determine to whom options will be granted, the number of options, the term, and the exercise price.										Common Stock:
	Options are to be granted at an exercise price not less than fair value for an ISO or 85% of fair value for an NSO. For individuals holding more than 10% of the voting rights of all classes of stock, the exercise price of an option will not be less than 110% of fair value. The vesting period is normally monthly over a period of four years from the vesting date. The contractual term of an option is no longer than five years for ISOs for which the grantee owns greater than 10% of the voting power of all classes of stock and no longer than ten years for all other options.
	The Company recognized stock-based compensation expense related to options granted to employees for the three months ended March 31, 2014 and 2015 of $11,000 and $401,000, respectively. The compensation expense is allocated on a departmental basis, based on the classification of the option holder. No income tax benefits have been recognized in the statements of operations for stock-based compensation arrangements.										The Company is authorized to issue 100,000,000 shares of common stock as of December 31, 2014 with a par value of $0.001 per share. As of December 31, 2013 and December 31, 2014, the Company had 535,685 and 6,769,106 shares, respectively, of common stock issued and outstanding.
	Stock compensation expense was allocated between departments as follows (in thousands):


			Three Months Ended March 31,								Upon the completion of the IPO on November 18, 2014, the 6,769,106 shares of common stock issued and outstanding consisted of the following:
			2014			2015
	Research and development		$	9		$	50
	Sales and marketing			—			20
	General and administrative			2			331				Legacy Shareholders		535,685
											Issued in connection with the IPO		1,650,000
	Total		$	11		$	401				Issued upon conversion of the 2014 convertible notes		552,105
											Issued upon conversion of the 2010/2012 convertible notes		3,165,887
	The fair value of each award granted was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions:										Issued upon conversion of the preferred stock		865,429

											Total		6,769,106
			Three Months Ended March 31,
			2014			2015
	Expected life (years)			5.8 - 6.1			5.5 - 6.1				Each share of common stock is entitled to one vote. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when and if declared by the Board of Directors, subject to the prior rights of all classes of stock outstanding. The holders of common stock, voting as a separate class, are entitled to elect one member of the Board of Directors.
	Risk-free interest rate			1.6% - 1.8%			1.5% - 1.6%
	Volatility			62% - 80%			57% - 68%				Convertible Preferred Stock:
	Dividend rate			0%			0%
	Expected volatility is based on volatilities of a group of public companies operating in the Company’s industry. The expected life of stock options represents the average of the contractual term of the options and the weighted-average vesting period, as permitted under the simplified method. The Company has elected to use the simplified method, as the Company does not have enough historical exercise experience to provide a reasonable basis upon which to estimate the expected term and the stock option grants are considered “plain vanilla” options. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant.										The Company is authorized to issue 1,860,000 shares of convertible preferred stock. The shares outstanding as of December 31, 2013 and December 31, 2014 are as follows:

	The following table summarizes stock option transactions as issued under the Plans:

											Series	Shares Outstanding
			Options			Number of			Average			Par Value		Shares		December 31,		December 31,
			Available			Shares			Exercise Price			Par Value		Authorized		2013		2014
	Balances, December 31, 2013			124,824			239,606		$	3.36	A	$	0.001		40,000		31,250		—
	2014 Plan authorized			1,437,165							B		0.001		320,000		119,140		—
	Closed 2010 Plan			(123,523	)						C		0.001		1,500,000		715,039		—
	Granted			(926,384	)		926,384		$	7.15
	Forfeited			93,979			(93,979	)	$	6.75					1,860,000		865,429		—

	Balances, December 31, 2014			606,061			1,072,011		$	6.34
	Authorized			270,764							In connection with the completion of the Company’s IPO on November 18, 2014, all shares of convertible preferred stock converted into 865,429 shares of common stock at a conversion ratio of one to one.
	Granted			(407,013	)		407,013		$	1.8
	Exercised						(2,083	)	$	5.76
	Forfeited			17,977			(17,977	)	$	4.94

	Balances, March 31, 2015			487,790			1,458,964		$	5.09

	Future stock-based compensation for unvested employee options granted and outstanding as of March 31, 2015 is approximately $0.9 million to be recognized over a remaining requisite service period of 3.6 years.
	The fair value of an equity award granted to a non-employee generally is determined in the same manner as an equity award granted to an employee. In most cases, the fair value of the equity securities granted is more reliably determinable than the fair value of the goods or services received. Stock-based compensation related to its grant of options to non-employees has not been material to date.
	2014 Employee Stock Purchase Plan
	Our board of directors and stockholders have adopted the 2014 Employee Stock Purchase Plan, or the ESPP. The ESPP has become effective, and our board of directors will implement commencement of offers thereunder in its discretion. A total of 139,839 shares of our common stock has been made available for sale under the ESPP. In addition, our ESPP provides for annual increases in the number of shares available for issuance under the plan on the first day of each year beginning in the year following the initial date that our board of directors authorizes commencement, equal to the least of:

		•		1.0% of the outstanding shares of our common stock on the first day of such year;

		•		279,680 shares; or

		•		such amount as determined by our board of directors.
	As of March 31, 2015 there were no purchases by employees under this plan.

	Common Stock Warrants
	As of March 31, 2015, the Company had 480,147 Common Stock warrants outstanding from the 2010/2012 convertible notes. During the first quarter of 2015, 43,720 common stock warrants were cashless exercised resulting in the issuance of 13,407 shares of the Company’s Common Stock. The Company also has outstanding 9,259 Common Stock warrants from 2009 and 82,500 Common Stock warrants issued to the underwriter in our IPO.

Stock_Option_Compensation

Stock Option Compensation	12 Months Ended
Stock Option Compensation	Dec. 31, 2014
Stock Option Compensation	Note 12. Stock Option Compensation

	Stock Option Plan

	The Company has adopted the 1999 Incentive Stock Plan, the 2010 Equity Incentive Plan, and the 2014 Equity Incentive Plan (together, the Plans). The 1999 Incentive Stock Plan expired in 2009, and the 2010 Equity Incentive Plan has been closed to new issuances. Therefore, the Company may issue options to purchase shares of common stock to employees, directors, and consultants only under the 2014 Equity Incentive Plan. Options granted under the 2014 Plan may be incentive stock options (“ISOs”) or nonqualified stock options (“NSOs”). ISOs may be granted only to Company employees and directors. NSOs may be granted to employees, directors, advisors, and consultants. The Board of Directors has the authority to determine to whom options will be granted, the number of options, the term, and the exercise price.



	Options are to be granted at an exercise price not less than fair value for an ISO or 85% of fair value for an NSO. For individuals holding more than 10% of the voting rights of all classes of stock, the exercise price of an option will not be less than 110% of fair value. The vesting period is normally monthly over a period of four years from the vesting date. The contractual term of an option is no longer than five years for ISOs for which the grantee owns greater than 10% of the voting power of all classes of stock and no longer than ten years for all other options.

	The Company recognized stock-based compensation expense related to options granted to employees for the fiscal years ended December 31, 2013 and 2014 of $38,417 and $345,435, respectively. The compensation expense is allocated on a departmental basis, based on the classification of the option holder. No income tax benefits have been recognized in the statements of operations for stock-based compensation arrangements as of December 31, 2013 and December 31, 2014.

	Stock compensation expense was allocated between departments as follows



		Year ended
		December 31,			December 31,
		2014			2013
	Research & Development	$	64,020		$	14,431
	Sales & Marketing	$	8,335			—
	General & Administrative	$	273,080		$	23,986

	Total	$	345,435		$	38,417

	The Company did not grant any stock options and no options were exercised during the year ended 12/31/2013. The Company granted options to purchase 926,384 of the Company’s common stock in 2014. The fair value of each award granted was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions for the year ended December 31, 2014:



		Year Ended
		December 31,
		2014
	Expected life (years)		5.8 - 6.1
	Risk-free interest rate		1.6 - 1.8%
	Volatility		43% - 59%
	Dividend rate		0%

	Expected volatility is based on volatilities of a group of public companies operating in the Company’s industry. The expected life of stock options represents the average of the contractual term of the options and the weighted-average vesting period, as permitted under the simplified method. The Company has elected to use the simplified method, as the Company does not have enough historical exercise experience to provide a reasonable basis upon which to estimate the expected term and the stock option grants are considered “plain vanilla” options. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant.



	The following table summarizes stock option transactions for the years ended December 31, 2013 and December 31, 2014 as issued under the Plans:



		Options			Number of			Average		Weighted
		Available			Shares			Exercise		Average
								Price		Grant Date
										Fair Value
										Per Option
	Balances, December 31, 2013		124,824			239,606			3.36
	2014 Plan authorized		1,437,165
	Closed 2010 Plan		(123,523	)
	Granted		(926,384	)		926,384			7.15	$	1.03
	Forfeited		93,979			(93,979	)		6.75	$	1.03

	Balances, December 31, 2014		606,061			1,072,011			6.34

	At December 31, 2013 and at December 31, 2014, there were 232,302 and 578,889 options to purchase shares, respectively, vested with a weighted-average exercise price of $3.36 and $5.58 per share, respectively, a weighted average contractual life of 3.86 and 7.46 years, respectively and a weighted average grant date fair value per option of $0.1 and $0.66, respectively. As of December 31, 2014, the outstanding stock options had an intrinsic value of $20,228. The weighted average remaining contractual term of the outstanding options was 8.67 years as of December 31, 2014.

	Future stock-based compensation for unvested employee options granted and outstanding as of December 31, 2014 is approximately $539,087 to be recognized over a remaining requisite service period of 3.88 years.

	The fair value of an equity award granted to a non-employee generally is determined in the same manner as an equity award granted to an employee. In most cases, the fair value of the equity securities granted is more reliably determinable than the fair value of the goods or services received. Stock-based compensation related to its grant of options to non-employees has not been material to date

GSK_License_Agreement

GSK License Agreement	12 Months Ended
GSK License Agreement	Dec. 31, 2014
GSK License Agreement	Note 13. GSK License Agreement

	In 2013, the Company entered into a license agreement with GSK in which GSK was to develop and commercialize the Company’s product, Serenz, on a world-wide basis. In 2013, the Company recognized license revenue of $3,000,000 due to a non-refundable payment upon execution of the agreement. In June 2014, the GSK agreement terminated and the licensed rights to Serenz were returned to the Company. Accordingly, the Company does not expect additional revenue to result from this agreement. Because the upfront payment was non-refundable, the Company is not obligated to return any of the funds as a result of the termination of the agreement. The Company does not have any continuing obligations under the GSK agreement.

Income_Taxes

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2014
Income Taxes	Note 14. Income Taxes

	Due to net losses in 2014 and 2013, the Company had no material current, deferred, or total income tax expense in the years ended December 31, 2014 and 2013. A reconciliation of income tax expense with amounts determined by applying the statutory U.S. federal income tax rate to income before income taxes is as follows:



			Years Ended December 31,
			2014			2013
			(revised)
	Tax on the loss before income tax expense computed at the federal statutory rate of 34%		$	(4,500,789	)	$	(1,260,190	)
	State tax (benefit) at statutory rate, net of federal benefit			(13,020	)		43,265
	Change in Valuation Allowance			1,578,347			779,869
	Change in research and development credits			316,311			(71,856	)
	Change in fair value of warrants			2,744,492			—
	Other			(125,341	)		508,912

	Income tax expense		$	—		$	—

	Effective income tax rate			0	%		0	%


	Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets and liabilities are as follows at December 31, 2014 and 2013:



			December 31,
			2014			2013
	Current Deferred Tax Assets:
	Accruals		$	71,953		$	36,571

	Non-Current Deferred Tax Assets:
	Net Operating Loss Carryforwards			22,125,807			20,124,059
	Research and development credits			1,345,833			1,792,798
	Intangible Assets			46,784			48,733
	Fixed Assets			(10,505	)		(636	)

	Total Non-Current Deferred Tax Assets			23,507,919			21,964,954

	Total Deferred Tax Assets			23,579,872			22,001,525

	Valuation Allowance			(23,579,872	)		(22,001,525	)

	Net Deferred Tax Assets		$	—		$	—


	The Company has recorded a full valuation allowance against its net deferred tax assets as it believes that it is more likely than not that such assets will not be realized. The valuation allowance increased by $1,578,347 from December 31, 2013 to December 31, 2014 primarily due to the generation of current year net operating losses and research and development credits claimed.



	As of December 31, 2014, the Company had $56,626,541 of federal and $49,238,708 of state net operating loss, respectively, available to offset future taxable income. The federal net operating loss carryforwards begins to expire in 2019 and the state net operating loss carryforwards will begin to expire in 2015, if not utilized. As of December 31, 2014, the Company also had $1,298,450 of federal and $945,710 of state research and development credit carryforwards, respectively. The federal research and development credit carryforward begins to expire in 2024 and the state research and development credit can be carryforward indefinitely.

	In addition, the use of net operating loss and tax credit carryforwards may be limited under Section 382 of the Internal Revenue Code in certain situations where changes occur in the stock ownership of a company. In the event that the Company has had a change in ownership, utilization of the carryforwards could be restricted.

	The following tables summarize the activities of gross unrecognized tax benefits:



			December 31,
			2014			2013
	Beginning balance			—			—
	Increase related to prior year tax positions			628,383			—
	Decreases related to prior year tax positions			—			—
	Increase related to Current year tax positions			44,864			—
	Decreases related to current year tax positions			—			—

Ending Balance		$	673,247			—


The amount of unrecognized tax benefits that would impact the effective tax rate were approximately none and none as of December 31, 2014 and December 31, 2013, respectively. As of December 31, 2014, $673,248 of unrecognized tax benefits would be offset by a change in valuation allowance.

In July 2013, the FASB issued guidance on the presentation of an unrecognized tax benefit when a net operating loss carryforward, similar tax loss or tax carryforward exists. FASB concluded that an unrecognized tax benefit should be presented as a reduction of a deferred tax asset except in certain circumstances the unrecognized tax benefit should be presented as a liability and should not be combined with deferred tax assets. The amendment is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013, with early adoption permitted. The Company adopted this guidance during the year ended December 31, 2014 and presented its unrecognized tax benefit as a reduction of deferred tax assets as of December 31, 2014.

The Company files income tax returns in the U.S. federal jurisdiction and certain state jurisdictions. In the normal course of business, the Company is subject to examination by federal, state and local jurisdictions, where applicable. In the U.S. federal jurisdiction, tax years 1999 forward remain open to examination, and in the state tax jurisdiction, years 2004 forward remain open to examination.

As a result of the expiration of the Company’s net operating loss carry-forwards, the Company has adopted the provisions set forth in FASB ASC Topic 740, to account for uncertainty in income taxes. In the preparation of income tax returns in federal and state jurisdictions, the Company asserts certain tax positions based on its understanding and interpretation of the income tax law. The taxing authorities may challenge such positions, and the resolution of such matters could result in recognition of income tax expense in the Company’s financial statements. Management believes it has used reasonable judgments and conclusions in the preparation of its income tax returns.

The Company uses the “more likely than not” criterion for recognizing the tax benefit of uncertain tax positions and to establish measurement criteria for income tax benefits. The Company has determined it has no material unrecognized assets or liabilities related to uncertain tax positions as of December 31, 2014. The Company does not anticipate any significant changes in such uncertainties and judgments during the next 12 months. In the event the Company should need to recognize interest and penalties related to unrecognized tax liabilities, this amount will be recorded as a component of other expense

Defined_Contribution_Plan

Defined Contribution Plan	12 Months Ended
Defined Contribution Plan	Dec. 31, 2014
Defined Contribution Plan	Note 15. Defined Contribution Plan

	The Company sponsors a 401(k) Plan, which stipulates that eligible employees can elect to contribute to the 401(k) Plan, subject to certain limitations of eligible compensation. The Company may match employee contributions in amounts to be determined at the Company’s sole discretion. To date, the Company has not made any matching contributions.

Subsequent_Events

Subsequent Events	3 Months Ended	12 Months Ended
Subsequent Events	Mar. 31, 2015	Dec. 31, 2014
Subsequent Events	Note 11. Subsequent Events	Note 16. Subsequent Events
	On April 1, 2015 the Company filed a registration statement on Form S-4 with the SEC to launch a formal tender/registered exchange offer to provide those holders of Series B Warrants that were not contacted pursuant to the Private Transaction, that was completed on March 5, 2015, the same opportunity to exercise such warrants for their cash exercise price and receive the same Series C Warrants, with an exercise price of $6.25 and a term of 5 years.
	Subsequent to March 31, 2015, in a number of transactions there were cashless exercises of 161,320 Series B Warrants, resulting in the issuance of 63,095 shares of the Company’s Common Stock.	On January 9, 2015, the Company entered into an agreement with Lucile Packard Foundation for Children’s Health, a charitable organization, to provide gifts totaling $210,000 during 2015. The purpose of the donation is to provide unrestricted support of the translational research efforts for Neonatal-Perinatal and Developmental Medicine under the direction of Dr. Vinod Bhutani. A portion of the funds may be provided to Beaumont Children’s Hospital, Royal Oak, MI; Albert Einstein Medical Center, Philadelphia, PA and McKay Dee Hospital & Intermountain Medical Center, Ogden, UT for research efforts provided by these collaborators.

		On February 2, 2015, the Company signed an amendment to its current lease agreement, extending the lease through June 2018. The amendment provides for monthly lease payments of $21,719 for the first year starting in June 2015, with modest increases in the following two years.

		On March 5, 2015, the Company entered into separate agreements with certain holders of the Company’s Series B warrants, who agreed to exercise their Series B warrants to purchase an aggregate of 589,510 shares of the Company’s common stock at an exercise price of $6.50 per share, resulting in gross proceeds to the Company of approximately $3.8 million. In connection with this exercise of the Series B warrants, the Company issued to each investor who exercised Series B warrants, new Series C warrants for the number of shares of the Company’s common stock underlying the Series B warrants that were exercised. Each Series C warrant will be exercisable at $6.25 per share and will expire on March 5, 2020. The new Series C warrants are exercisable into 589,510 shares of the Company’s common stock.

		The Company intends to offer all remaining holders of Series B warrants, through the Exchange Offer, the opportunity to exercise the Series B warrants held by them and receive Series C warrants with the same terms indicated above.

Liquidity_Financial_Condition_

Liquidity, Financial Condition and Management's Plans	3 Months Ended
Liquidity, Financial Condition and Management's Plans	Mar. 31, 2015
Liquidity, Financial Condition and Management's Plans	Note 2. Liquidity, Financial Condition and Management’s Plans
	The Company incurred a loss of $11.6 million for the quarterly period ended March 31, 2015 and has an accumulated deficit of approximately $82.0 million from having incurred losses since its inception. The Company’s current period loss includes approximately $9.2 million of non-cash charges relating to the fair value of derivative liabilities and approximately $0.4 million of stock based compensation. The Company has approximately $9.0 million of working capital at March 31, 2015 but used approximately $1.8 million of cash in its operating activities during the period. The Company has financed its operations principally through issuances of debt and equity securities. The Company completed its IPO on November 18, 2014 upon the issuance of 1,650,000 units, each of which consisted of one share of common stock, one Series A Warrant and one Series B Warrant, at an offering price of $6.50 per unit and received net proceeds of $8.0 million, after deducting underwriting discounts and commissions and IPO related expenses. The Series A Warrants are registered securities that are freely tradable on the NASDAQ. The Series B Warrants have variable settlement provisions (see Note 6). On March 5, 2015 the Company received approximately $3.8 million as a result of Series B Warrant holders exercising warrants to purchase shares of the Company’s Common Stock (the “Private Transaction”). In addition, on March 6, 2015 the Company received approximately $0.2 million as a result of Series A Warrant holders exercising warrants to purchase shares of the Company’s Common Stock. On March 31, 2015 the Company received $12 thousand from the exercise of stock options. Management believes that the Company has sufficient capital resources to sustain operations through at least May 5, 2016.
	The Company expects to continue incurring losses for the foreseeable future and may be required to raise additional capital to pursue its product development initiatives and penetrate markets for the sale of its products. The Company cannot provide any assurance that it will raise additional capital. Management believes that the Company has access to capital resources through possible public or private equity offerings, debt financings, corporate collaborations or other means; however, the Company has not secured any commitment for new financing at this time nor can it provide any assurance that new financing will be available on commercially acceptable terms, if at all. If the Company is unable to secure additional capital, it may be required to curtail its development of new products and take additional measures to reduce costs in order to conserve its cash in amounts sufficient to sustain operations and meet its obligations. These measures could cause significant delays in the Company’s efforts to commercialize its products, which is critical to the realization of its business plan and the future operations of the Company.

Net_loss_per_share

Net loss per share	3 Months Ended
Net loss per share	Mar. 31, 2015
Net loss per share	Note 10. Net loss per share
	Basic net loss per share is computed by dividing net loss by the weighted-average number of common stock actually outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common stock outstanding and dilutive potential common stock that would be issued upon the conversion of preferred stock. For the three months ended March 31, 2014 and 2015, the effect of issuing the potential common stock is anti-dilutive due to the net losses in those periods and the number of shares used to compute basic and diluted earnings per share are the same for each of those periods.
	The following is a reconciliation of the number of shares used in the calculation of basic earnings per share and diluted earnings per share during the three months ended March 31, 2014 and 2015 (in thousands, except per share and share data):


		Three Months Ended
		March 31,
		2014			2015
	Net loss	$	(834	)	$	(11,651	)

	Weighted-average shares used in computing basic and diluted net loss per common share		535,685			6,965,483
	Basic and diluted net loss per common share	$	(1.56	)	$	(1.67	)

	The following potentially dilutive securities outstanding have been excluded from the computations of diluted weighted-average shares outstanding because such securities have an antidilutive impact due to losses reported (in common stock equivalent shares):


		Three Months Ended March 31,
		2015			2014
	Convertible preferred stock		—			865,429
	Warrants issued to 2010/2012 convertible note holders to purchase common stock		480,147			523,867
	Options to purchase common stock		1,458,964			228,223
	Warrants issued in 2009 to purchase common stock		9,259			9,259
	Warrants issued to underwriter to purchase common stock		82,500			—
	Series A warrants to purchase common stock		2,425,605			—
	Series B warrants to purchase common stock		1,778,275			—
	Series C warrants to purchase common stock		589,510			—

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)

3 Months Ended

12 Months Ended

Mar. 31, 2015

Dec. 31, 2014

Basis of Presentation

Significant Risks and Uncertainties

Use of Estimates

Concentration of Credit Risk

Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents at two commercial banks that management believes are of high credit quality. Cash and cash equivalents deposited with these commercial banks exceeded the Federal Deposit Insurance Corporation insurable limit at December 31, 2014 and 2013. The Company expects this to continue.

Segments

Cash and Cash Equivalents

Prepaid Expenses and Other Current Assets

Accounts Receivable

Inventory

Property and Equipment, Net

Convertible Instruments

The Company evaluates and accounts for conversion options embedded in its convertible instruments in accordance with ASC 815 “Derivatives and Hedging.”

Common Stock Purchase Warrants and Other Derivative Financial Instruments

Convertible Preferred Stock Warrant Liability

Series A Warrant Liability

(including, without limitation, a reorganization, recapitalization, spin-off or other scheme of arrangement), then each registered holder of outstanding Series A Warrants as at any time prior to the consummation of the Fundamental Transaction, may elect and require the Company to purchase the Series A Warrants held by such person immediately prior to the consummation of such Fundamental Transaction by making a cash payment in an amount equal to the Black Scholes Value of the remaining unexercised portion of such registered holder’s Series A Warrants. Therefore, under ASC 815, the Company classified the fair value of these Series A Warrants as liabilities on the balance sheet due to this possibility that the Company may be obligated to settle the warrants in cash. As the warrants are publicly traded, the Company uses the closing price on the measurement date to determine the fair value of these warrants.

Series B Warrant Liability

Convertible Preferred Stock

At the time of the IPO, all outstanding shares of preferred stock converted into common stock at a conversion rate of one to one, and were reclassified to permanent equity.

Revenue Recognition

The Company began recognizing sales of CoSense during the three months ended March 31, 2015. The Company recognizes revenue when all of the following criteria are met:

•

persuasive evidence of an arrangement exists;

•

the sales price is fixed or determinable;

•

collection of the relevant receivable is probable at the time of sale; and

•

delivery has occurred or services have been rendered.

Research and Development

Income Taxes

Stock-Based Compensation

Comprehensive Income (Loss)

Net Income (Loss) per Share of Common Stock

The following is a reconciliation of the number of shares used in the calculation of basic earnings per share and diluted earnings per share during the years ended December 31, 2014 and 2013:

Fiscal Year Ended

December 31,

2014

2013

(revised)

Net loss

(13,237,616

)

(3,707,243

)

Weighted-average shares used in computing basic and diluted net loss per common share

1,270,033

535,648

Basic and diluted net loss per common share

(10.42

)

(6.92

)

Effective as of the completion of the IPO, all of the Company’s preferred stock was converted to common stock.

Fiscal Year Ended

December 31,

2014

2013

Convertible preferred stock

—

865,429

Warrants issued to 2010/2012 convertible note holders to purchase stock

523,867

Adjustable

Stock issuable upon conversion of convertible notes

—

Adjustable

Options to purchase common stock

1,072,011

239,606

Warrants issued in 2009 to purchase stock

9,259

Warrants issued to Underwriter to purchase common stock

82,500

—

Series A Warrants to purchase common stock

2,449,605

—

Series B Warrants to purchase common stock

Adjustable

—

Reverse Stock Split

Recent Accounting Pronouncements

The Company has considered all other recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements.

Fair Value of Financial Instruments

The carrying value of the Company’s cash, accounts receivable, prepaid expenses and other current assets, accounts payable, and accrued liabilities approximate fair value due to the short-term nature of these items. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the convertible promissory notes approximates their fair value.

Fair Value Measurement

Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.

Description_of_Business_Tables

Description of Business (Tables) (IPO [Member])	12 Months Ended
Description of Business (Tables) (IPO [Member])	Dec. 31, 2014
IPO [Member]
Summary of Initial Public Offering	The following table summarizes the results of the Company’s IPO:


	Transaction	Number of		Common		Proceeds
	Transaction	Units		Stock		Proceeds
	Units Issued in IPO		1,650,000		1,650,000	$	10,708,500
	Issuance of A & B Warrants (overallotment to underwriters)		—		—	$	18,975
	Conversion of preferred Stock (one for one conversion ratio)		—		865,429		—
	2010/2012 Convertible notes		—		3,165,887		—
	2014 Convertible Notes		552,105		552,105		—

	Totals		2,202,105		6,233,421	$	10,727,475

Net_loss_per_share_Tables

Net loss per share (Tables)	3 Months Ended							12 Months Ended
Net loss per share (Tables)	Mar. 31, 2015							Dec. 31, 2014
Schedule of Calculation of Basic Earnings per Share and Diluted Earnings per Share	The following is a reconciliation of the number of shares used in the calculation of basic earnings per share and diluted earnings per share during the three months ended March 31, 2014 and 2015 (in thousands, except per share and share data):							The following is a reconciliation of the number of shares used in the calculation of basic earnings per share and diluted earnings per share during the years ended December 31, 2014 and 2013:


		Three Months Ended
		March 31,							Fiscal Year Ended
		2014			2015				December 31,
	Net loss	$	(834	)	$	(11,651	)		2014			2013
									(revised)
	Weighted-average shares used in computing basic and diluted net loss per common share		535,685			6,965,483		Net loss	$	(13,237,616	)	$	(3,707,243	)
	Basic and diluted net loss per common share	$	(1.56	)	$	(1.67	)
								Weighted-average shares used in computing basic and diluted net loss per common share		1,270,033			535,648
								Basic and diluted net loss per common share	$	(10.42	)	$	(6.92	)
Schedule of Potentially Dilutive Securities Outstanding Excluded from Computations of Diluted Weighted-Average Shares Outstanding	The following potentially dilutive securities outstanding have been excluded from the computations of diluted weighted-average shares outstanding because such securities have an antidilutive impact due to losses reported (in common stock equivalent shares):							The following potentially dilutive securities outstanding have been excluded from the computations of diluted weighted-average shares outstanding because such securities have an antidilutive impact due to losses reported (in common stock equivalent shares):


		Three Months Ended March 31,							Fiscal Year Ended
		2015			2014				December 31,
	Convertible preferred stock		—			865,429			2014			2013
	Warrants issued to 2010/2012 convertible note holders to purchase common stock		480,147			523,867		Convertible preferred stock		—			865,429
	Options to purchase common stock		1,458,964			228,223		Warrants issued to 2010/2012 convertible note holders to purchase stock		523,867			Adjustable
	Warrants issued in 2009 to purchase common stock		9,259			9,259		Stock issuable upon conversion of convertible notes		—			Adjustable
	Warrants issued to underwriter to purchase common stock		82,500			—		Options to purchase common stock		1,072,011			239,606
	Series A warrants to purchase common stock		2,425,605			—		Warrants issued in 2009 to purchase stock		9,259			9,259
	Series B warrants to purchase common stock		1,778,275			—		Warrants issued to Underwriter to purchase common stock		82,500			—
	Series C warrants to purchase common stock		589,510			—		Series A Warrants to purchase common stock		2,449,605			—
								Series B Warrants to purchase common stock		Adjustable			—

Revision_of_Prior_Year_Financi1

Revision of Prior Year Financial Statements (Tables)	3 Months Ended										12 Months Ended
Revision of Prior Year Financial Statements (Tables)	Mar. 31, 2015										Dec. 31, 2014
Revised Prior Period Balances	The following table sets forth the revised prior period balances reported in our our comparative financial statements as if adjustments had been made:										The following table sets forth the revised balances reported in our comparative financial statements as if adjustments had been made:


	(in thousands except per share data)	Previously			Adjustment			Revised			(in thousands except per share data)	Previously			Adjustment			Revised
	(in thousands except per share data)	reported			Adjustment			Revised			(in thousands except per share data)	reported			Adjustment			Revised
	Balance sheet items at December 31, 2014:										Balance sheet items at December 31, 2014:
	Current liabilities	$	1,290		$	—		$	1,290		Current liabilities	$	1,290		$	—		$	1,290
	Series A warrant liability		—			857			857
	Series B warrant liability		17,439			—			17,439		Series A warrant liability		—			857			857

	Total liabilities		18,729			857			19,586		Series B warrant liability		17,439			—			17,439
	Additional paid-in capital		60,636			(1,494	)		59,141
	Accumulated deficit		(70,975	)		637			(70,338	)	Total liabilities		18,729			857			19,586

	Total stockholders’ deficit		(10,333	)		(857	)		(11,190	)	Additional paid-in capital		60,636			(1,494	)		59,141

	Liabilities and stockholders’ deficit	$	8,396		$	—		$	8,396		Accumulated deficit		(70,975	)		637			(70,338	)

	Statement of operations items for the year ended December 31, 2014										Total stockholders’ deficit		(10,333	)		(857	)		(11,190	)
	Other income (expense)	$	(4,585	)	$	637		$	(3,949	)
											Liabilities and stockholders’ deficit	$	8,396		$	—		$	8,396
	Net loss	$	(13,875	)	$	637			(13,238	)

	Basic and diluted net loss per common share	$	(10.92	)	$	0.5			(10.42	)	Statement of operations items for the year ended December 31, 2014

											Other income (expense)	$	(4,585	)	$	637		$	(3,949	)


											Net loss	$	(13,875	)	$	637			(13,238	)


											Basic and diluted net loss per common share	$	(10.92	)	$	0.5			(10.42	)

Fair_Value_of_Financial_Instru1

Fair Value of Financial Instruments (Tables)	3 Months Ended																		12 Months Ended
Fair Value of Financial Instruments (Tables)	Mar. 31, 2015																		Dec. 31, 2014
Summary of Financial Instruments Measured at Fair Value on Recurring Basis	The following table sets forth the Company’s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):																		The following table sets forth the Company’s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy:


		Fair Value Measurements at December 31, 2014 (revised)																		Fair Value Measurements at December 31, 2013
		Total			Level 1			Level 2			Level 3									Total		Level 1		Level 2		Level 3
	Assets																		Assets
	Money market fund	$	7,892		$	7,892		$	—		$	—							Money market fund	$	1,256,752	$	1,256,752	$	—	$	—

	Liabilities																		Liabilities
	Series A warrant liability	$	857		$	857		$	—		$	—							Convertible preferred stock warrant liability	$	1,464,877	$	—	$	—	$	1,464,877
	Series B warrant liability		17,439			—			—			17,439

	Total common stock warrant liability	$	18,296		$	857		$	—		$	17,439								Fair Value Measurements at December 31, 2014 (revised)
																				Total		Level 1		Level 2		Level 3
																			Assets
																			Money market fund	$	7,892	$	7,892	$	—	$	—
		Fair Value Measurements at March 31, 2015
		Total			Level 1			Level 2			Level 3								Liabilities
	Assets																		Series A warrant liability	$	857	$	857	$	—	$	—
	Money market fund	$	6,472		$	6,472		$	—		$	—							Series B warrant liability		17,439		—		—		17,439

	Liabilities																		Total common stock warrant liability	$	18,296	$	857	$	—	$	17,349
	Series A warrant liability		3,582			3,582			—			—
	Series B warrant liability		14,180			—			—			14,180
	Series C warrant liability		2,549			—			—			2,549

	Total common stock warrant liability	$	20,311		$	3,582		$	—		$	16,729

Summary of Changes in Fair Value of Level1 and Level 3 Financial Instruments	The following table sets forth a summary of the changes in the fair value of the Company’s Level 1 and Level 3 financial instruments, which are treated as liabilities, as follows:


		Series A Warrant						Series B Warrant						Series C Warrant
		Number of			Liability			Number of			Liability			Number of		Liability
		Warrants			Liability			Warrants			Liability			Warrants		Liability
					(in thousands)						(in thousands)					(in thousands)
	Balance at December 31, 2014 (revised)		2,449,605		$	857			2,449,605		$	17,439			—	$	—
	Change in value of Series A Warrants		—			2,767			—			—			—		—
	De-recognition of Series A Warrant liability upon exercise		(24,000	)		(42	)		—			—			—		—
	De-recognition of Series B Warrant liability upon cash exercise of 589,510 warrants in Private Transaction (589,510 shares issued)		—			—			(589,510	)		(6,430	)		—		—
	De-recognition of Series B Warrant liability for other cash exercises of 29,097 warrants (29,097 shares issued)		—			—			(29,097	)		(317	)		—		—
	De-recognition of Series B Warrant liability upon cashless exercise of 52,255 warrants (21,186 shares issued)		—			—			(52,255	)		(418	)		—		—
	De-recognition of Series B Warrant liability upon contribution of 468 warrants back to the Company		—			—			(468	)		(3	)		—		—
	Change in value of Series B Warrants		—			—			—			3,909			—		—
	Record Series C Warrant Liability		—			—			—			—			589,510		3,050
	Change in value of Series C Warrants		—			—			—			—			—		(501	)

	Balance at March 31, 2015		2,425,605		$	3,582			1,778,275		$	14,180			589,510	$	2,549

Property_and_Equipment_Net_Tab

Property and Equipment, Net (Tables)	12 Months Ended
Property and Equipment, Net (Tables)	Dec. 31, 2014
Schedule of Property and Equipment	Property and equipment consisted of the following:


		December 31,			December 31,
		2014			2013
	Furniture and fixtures	$	170,811		$	180,238
	Computer hardware		27,555			27,555
	Leasehold improvements		4,075			10,726

		$	202,441		$	218,519
	Less accumulated depreciation and amortization		(144,834	)		(155,352	)

	Total	$	57,607		$	63,167

Convertible_Preferred_Stock_Wa1

Convertible Preferred Stock Warrants (Tables)	3 Months Ended							12 Months Ended
Convertible Preferred Stock Warrants (Tables)	Mar. 31, 2015							Dec. 31, 2014
Fair Value of Convertible Preferred Stock Warrant Liability								As of December 31, 2013, the Company used a Monte Carlo simulation to calculate the fair value of its convertible preferred stock warrant liability using the following inputs:


									December 31,
									2013
								Volatility		38% - 47%
								Expected Term (years)		0.75 - 2.00
								Expected dividend yield		0.00%
								Risk-free rate		0.12% - 0.38%
Summary of Outstanding Convertible Preferred Stock Warrants								As of December 31, 2013 and November 18, 2014 (IPO date), outstanding convertible preferred stock warrants consisted of:


								Issuance date	Contractual		Exercise price per				Number of shares		Fair Value at		Fair Value at
									Term		share				underlying		December 31, 2013		November 18, 2014
															warrant
								Jan-09	10 years		$	21.6				9,259	$	42,444		2,911
								2010/2012	10 years			Adjustable				Adjustable		1,422,433		1,217,808

								Total									$	1,464,877		1,220,719

Series B Warrant liability [Member]
Fair Value of Convertible Preferred Stock Warrant Liability	As December 31, 2014, and March 31, 2015 the Company used a Monte Carlo simulation to calculate the fair value of its Series B Warrant liability. This model is dependent upon several variables such as the warrant’s term, exercise price, current stock price, risk-free interest rate estimated over the contractual term, estimated volatility of our stock over the term of warrant and the estimated market price of our stock during the cashless exercise period. The risk-free rate is based on U.S. Treasury securities with similar maturities as the expected terms of the warrants. The volatility is estimated based on blending the volatility rates for a number of similar publicly-traded companies. The Company used the following inputs:							As of November 18, 2014 and December 31, 2014, the Company used a Monte Carlo simulation to calculate the fair value of its Series B Warrant liability. This model is dependent upon several variables such as the warrant’s term, exercise price, current stock price, risk-free interest rate estimated over the contractual term, estimated volatility of our stock over the term of warrant and the estimated market price of our stock during the cashless exercise period. The risk-free rate is based on U.S. Treasury securities with similar maturities as the expected terms of the warrants. The volatility is estimated based on blending the volatility rates for a number of similar publicly-traded companies. The Company used the following inputs:


		December 31,			March 31,				November 18,				December 31,
		2014			2015				2014				2014
	Volatility		86.6	%		100	%	Volatility		64	%			86	%
	Expected Term (years)		1.1			0.87		Expected Term (years)		1.25				1.1
	Expected dividend yield		0	%		0	%	Expected dividend yield		0	%			0	%
	Risk-free rate		0.26	%		0.26	%	Risk-free rate		0.2	%			0.26	%
Series C Warrant liability [Member]
Fair Value of Convertible Preferred Stock Warrant Liability	The Company has calculated the fair value of the Series C warrants using a Black-Scholes pricing model, which requires the input of highly subjective assumptions including the expected stock price volatility. The Company used the following inputs:


		March 4,			March 31,
		2015			2015
	Volatility		86	%		86	%
	Expected Term (years)		5			4.93
	Expected dividend yield		0	%		0	%
	Risk-free rate		1.37	%		1.35	%
IPO [Member]
Fair Value of Convertible Preferred Stock Warrant Liability								completed. The Company used a Black Scholes model to calculate the value of these warrants on November 18, 2014 using the following inputs:


									November 18,
									2014
								Volatility		61% -71.2%
								Contractual Term (years)		4.5 -7.5
								Expected dividend yield		0.00%
								Risk-free rate		1.50% -2.09%
								Stock Price		$4.00
								Exercise Price		$4.87 - $21.60

Warrant_Liabilities_Tables

Warrant Liabilities (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2015

Dec. 31, 2014

Summary of Outstanding Series A Warrants and Fair Market Values

As of December 31, 2014 and March 31, 2015 the outstanding Series B Warrants and fair market values were:

Issuance date

Contractual

Exercise price

Shares Underlying

Number of

Fair Value at

Number of

Fair Value at

Term

per share

warrants

Warrants at

December 31, 2014

Warrants at

March 31, 2015

December 31, 2014

(in thousands)

March 31, 2015

(in thousands)

Nov-14

15 months

6.5

Adjustable

2,449,605

17,439

1,778,275

14,180

Series A Warrant liability [Member]

Summary of Outstanding Series A Warrants and Fair Market Values

As of November 18, 2014 and December 31, 2014, the outstanding Series A Warrants and fair market values were:

Issuance date

Contractual

Exercise price per

Number of

Shares underlying

Fair Value at

Term

warrants

November 18, 2014

December 31, 2014

Nov-14

5 years

6.5

2,449,605

1,494,259

857,362

Series B Warrant liability [Member]

Summary of Outstanding Series A Warrants and Fair Market Values

As of November 18, 2014 and December 31, 2014, the outstanding Series B Warrants and fair market values were:

Issuance date

Contractual

Exercise price per

Number of

Shares underlying

Fair Value at

Term

warrants

November 18, 2014

December 31, 2014

Nov-14

15 months

Adjustable

2,449,605

Adjustable

11,649,106

17,438,731

Stockholders_Deficit_Tables

Stockholders' Deficit (Tables)	3 Months Ended									12 Months Ended
Stockholders' Deficit (Tables)	Mar. 31, 2015									Dec. 31, 2014
Summary of Common Stock Issued and Outstanding										Upon the completion of the IPO on November 18, 2014, the 6,769,106 shares of common stock issued and outstanding consisted of the following:


										Legacy Shareholders		535,685
										Issued in connection with the IPO		1,650,000
										Issued upon conversion of the 2014 convertible notes		552,105
										Issued upon conversion of the 2010/2012 convertible notes		3,165,887
										Issued upon conversion of the preferred stock		865,429

										Total		6,769,106

Summary of Convertible Preferred Stock										The Company is authorized to issue 1,860,000 shares of convertible preferred stock. The shares outstanding as of December 31, 2013 and December 31, 2014 are as follows:


										Series	Shares Outstanding
											Par Value			Shares			December 31,		December 31,
											Par Value			Authorized			2013		2014
										A	$	0.001			40,000			31,250		—
										B		0.001			320,000			119,140		—
										C		0.001			1,500,000			715,039		—

															1,860,000			865,429		—

Summary of Stock Based Compensation Expense	Stock compensation expense was allocated between departments as follows (in thousands):									Stock compensation expense was allocated between departments as follows


		Three Months Ended March 31,									Year ended
		2014			2015						December 31,			December 31,
	Research and development	$	9		$	50					2014			2013
	Sales and marketing		—			20				Research & Development	$	64,020		$	14,431
	General and administrative		2			331				Sales & Marketing	$	8,335			—
										General & Administrative	$	273,080		$	23,986
	Total	$	11		$	401
										Total	$	345,435		$	38,417
Schedule of Fair Value of Award Granted Using Black-Scholes Option Pricing Model	The fair value of each award granted was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions:									The fair value of each award granted was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions for the year ended December 31, 2014:


		Three Months Ended March 31,									Year Ended
		2014			2015						December 31,
	Expected life (years)		5.8 - 6.1			5.5 - 6.1					2014
	Risk-free interest rate		1.6% - 1.8%			1.5% - 1.6%				Expected life (years)		5.8 - 6.1
	Volatility		62% - 80%			57% - 68%				Risk-free interest rate		1.6 - 1.8%
	Dividend rate		0%			0%				Volatility		43% - 59%
										Dividend rate		0%
Summary of Stock Option Transactions	The following table summarizes stock option transactions as issued under the Plans:									The following table summarizes stock option transactions for the years ended December 31, 2013 and December 31, 2014 as issued under the Plans:


		Options			Number of			Average			Options			Number of			Average		Weighted
		Available			Shares			Exercise Price			Available			Shares			Exercise		Average
	Balances, December 31, 2013		124,824			239,606		$	3.36								Price		Grant Date
	2014 Plan authorized		1,437,165																Fair Value
	Closed 2010 Plan		(123,523	)															Per Option
	Granted		(926,384	)		926,384		$	7.15	Balances, December 31, 2013		124,824			239,606			3.36
	Forfeited		93,979			(93,979	)	$	6.75	2014 Plan authorized		1,437,165
										Closed 2010 Plan		(123,523	)
	Balances, December 31, 2014		606,061			1,072,011		$	6.34	Granted		(926,384	)		926,384			7.15	$	1.03
	Authorized		270,764							Forfeited		93,979			(93,979	)		6.75	$	1.03
	Granted		(407,013	)		407,013		$	1.8
	Exercised					(2,083	)	$	5.76	Balances, December 31, 2014		606,061			1,072,011			6.34
	Forfeited		17,977			(17,977	)	$	4.94

	Balances, March 31, 2015		487,790			1,458,964		$	5.09

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2014
Reconciliation of Income Tax Expense by Applying Statutory U.S. Federal Income Tax Rate to Income Before Income Taxes	A reconciliation of income tax expense with amounts determined by applying the statutory U.S. federal income tax rate to income before income taxes is as follows:



		Years Ended December 31,
		2014			2013
		(revised)
	Tax on the loss before income tax expense computed at the federal statutory rate of 34%	$	(4,500,789	)	$	(1,260,190	)
	State tax (benefit) at statutory rate, net of federal benefit		(13,020	)		43,265
	Change in Valuation Allowance		1,578,347			779,869
	Change in research and development credits		316,311			(71,856	)
	Change in fair value of warrants		2,744,492			—
	Other		(125,341	)		508,912

	Income tax expense	$	—		$	—

	Effective income tax rate		0	%		0	%
Significant Components of Company's Deferred Tax Assets and Liabilities	Significant components of the Company’s deferred tax assets and liabilities are as follows at December 31, 2014 and 2013:


		December 31,
		2014			2013
	Current Deferred Tax Assets:
	Accruals	$	71,953		$	36,571

	Non-Current Deferred Tax Assets:
	Net Operating Loss Carryforwards		22,125,807			20,124,059
	Research and development credits		1,345,833			1,792,798
	Intangible Assets		46,784			48,733
	Fixed Assets		(10,505	)		(636	)

	Total Non-Current Deferred Tax Assets		23,507,919			21,964,954

	Total Deferred Tax Assets		23,579,872			22,001,525

	Valuation Allowance		(23,579,872	)		(22,001,525	)

	Net Deferred Tax Assets	$	—		$	—

Summary of Gross Unrecognized Tax Benefits	The following tables summarize the activities of gross unrecognized tax benefits:


		December 31,
		2014			2013
	Beginning balance		—			—
	Increase related to prior year tax positions		628,383			—
	Decreases related to prior year tax positions		—			—
	Increase related to Current year tax positions		44,864			—
	Decreases related to current year tax positions		—			—

	Ending Balance	$	673,247			—

Description_of_Business_Additi

Description of Business - Additional Information (Detail) (USD $)	3 Months Ended	12 Months Ended	0 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Nov. 18, 2014	Dec. 31, 2013
Description Of Business [Line Items]
State of incorporation	Delaware	Delaware
Date of incorporation	25-Aug-99	25-Aug-99
Deferred revenue recognized		$0
Net proceeds after deducting underwriting discounts and commissions and IPO related expenses		10,727,475
Series B Warrants to Purchase Shares of Common Stock [Member]
Description Of Business [Line Items]
Number of common stock purchased upon issuance of warrants	2,449,605
IPO [Member]
Description Of Business [Line Items]
Net proceeds after deducting underwriting discounts and commissions and IPO related expenses			8,000,000
IPO [Member] \| Series A Warrants to Purchase Shares of Common Stock [Member]
Description Of Business [Line Items]
Number of warrants			2,449,605
Number of common stock purchased upon issuance of warrants			2,449,605
IPO [Member] \| Series B Warrants to Purchase Shares of Common Stock [Member]
Description Of Business [Line Items]
Number of warrants			2,449,605
IPO [Member] \| Warrants to Purchase Stock [Member]
Description Of Business [Line Items]
Debt conversion, warrants issued			523,867
Units [Member] \| IPO [Member]
Description Of Business [Line Items]
Description of units issued	1,650,000 units, each of which consisted of one share of common stock, one Series A Warrant and one Series B Warrant.	1,650,000 units (each unit consisting of one share of common stock, one Series A warrant and one Series B warrant)
Number of shares issued		1,650,000	1,650,000
Net proceeds after deducting underwriting discounts and commissions and IPO related expenses		10,708,500	8,000,000
GlaxoSmithKline [Member]
Description Of Business [Line Items]
Deferred revenue recognized				$3,000,000

Description_of_Business_Summar

Description of Business - Summary of Initial Public Offering (Detail) (USD $)	0 Months Ended	12 Months Ended
	Nov. 18, 2014	Dec. 31, 2014
Description Of Business [Line Items]
Proceeds from intimal public offering		$10,727,475
IPO [Member]
Description Of Business [Line Items]
Proceeds from intimal public offering	8,000,000
IPO [Member] \| 2014 Convertible Promissory Notes [Member]
Description Of Business [Line Items]
Convertible notes	552,105
Units [Member] \| 2014 Convertible Promissory Notes [Member]
Description Of Business [Line Items]
Convertible notes	552,105
Units [Member] \| IPO [Member]
Description Of Business [Line Items]
Units Issued in IPO	1,650,000	1,650,000
Totals		2,202,105
Proceeds from intimal public offering	8,000,000	10,708,500
Units [Member] \| IPO [Member] \| 2014 Convertible Promissory Notes [Member]
Description Of Business [Line Items]
Convertible notes		552,105
Series A & B Warrants [Member] \| IPO [Member]
Description Of Business [Line Items]
Proceeds from intimal public offering		$18,975
Common Stock [Member]
Description Of Business [Line Items]
Units Issued in IPO		1,650,000
Conversion of preferred Stock (one for one conversion ratio)	865,429
Common Stock [Member] \| 2010 and 2012 Convertible Promissory Notes [Member]
Description Of Business [Line Items]
Conversion of preferred Stock (one for one conversion ratio)		3,165,887
Common Stock [Member] \| 2014 Convertible Promissory Notes [Member]
Description Of Business [Line Items]
Conversion of preferred Stock (one for one conversion ratio)		552,105
Common Stock [Member] \| IPO [Member]
Description Of Business [Line Items]
Units Issued in IPO		1,650,000
Conversion of preferred Stock (one for one conversion ratio)	865,429	865,429
Totals		6,233,421
Common Stock [Member] \| IPO [Member] \| 2010 and 2012 Convertible Promissory Notes [Member]
Description Of Business [Line Items]
Convertible notes	3,165,887	3,165,887
Common Stock [Member] \| IPO [Member] \| 2014 Convertible Promissory Notes [Member]
Description Of Business [Line Items]
Convertible notes		552,105

Summary_of_Significant_Account2

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	12 Months Ended	0 Months Ended		11 Months Ended	12 Months Ended
	Dec. 31, 2014	Nov. 18, 2014	Mar. 05, 2015	Feb. 12, 2016	Dec. 31, 2013	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2012
	Segment	Nov. 18, 2014	Mar. 05, 2015	Feb. 12, 2016	Dec. 31, 2013	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2012
Schedule Of Significant Accounting Policies [Line Items]
Accumulated deficit	($70,338,126)				($57,100,511)	($81,989,000)
Cash and cash equivalents	7,956,710				1,268,770	9,529,000	764,000	2,155,262
Net proceeds from issuance of IPO	10,727,475
Number of operating segments	1
Allowance for doubtful accounts					0
Deferred revenue recognized	0
Reverse stock split description	1-for-12 reverse split of shares
Money market fund	7,900,000					6,500,000
Inventory, raw material						110,000
Inventory, work-in-process						61,000
Inventory, finished goods						35,000
IPO [Member]
Schedule Of Significant Accounting Policies [Line Items]
Net proceeds from issuance of IPO		8,000,000
Series B Warrant liability [Member]
Schedule Of Significant Accounting Policies [Line Items]
Exercise of warrants to purchase of common stock			3,800,000
Series B Warrant liability [Member] \| Subsequent event [Member]
Schedule Of Significant Accounting Policies [Line Items]
Exercise of warrants to purchase of common stock			3,800,000
Series B Warrants to Purchase Common Stock [Member] \| Scenario Forecast [Member]
Schedule Of Significant Accounting Policies [Line Items]
Decrease in common stock market price				$6.50
Minimum [Member]
Schedule Of Significant Accounting Policies [Line Items]
Estimated useful lives of property and equipment	3 years
Maximum [Member]
Schedule Of Significant Accounting Policies [Line Items]
Estimated useful lives of property and equipment	5 years
GlaxoSmithKline [Member]
Schedule Of Significant Accounting Policies [Line Items]
Proceeds from license agreement					3,000,000
Deferred revenue recognized					$3,000,000

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Schedule of Calculation of Basic Earnings per Share and Diluted Earnings per Share (Detail) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Net loss	($11,651,000)	($834,000)	($13,237,616)	($3,707,243)
Weighted-average shares used in computing basic and diluted net loss per common share	6,965,483	535,685	1,270,033	535,648
Basic and diluted net loss per common share	($1.67)	($1.56)	($10.42)	($6.92)

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Outstanding Excluded from Computations of Diluted Weighted-Average Shares Outstanding (Detail)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computations of diluted weighted-average shares outstanding		865,429		865,429
Stock Issuable Upon Conversion of Convertible Notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computations of diluted weighted-average shares outstanding
Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computations of diluted weighted-average shares outstanding	1,458,964	228,223	1,072,011	239,606
Warrants to Purchase Stock [Member] \| 2010 and 2012 Convertible Promissory Notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computations of diluted weighted-average shares outstanding	480,147	523,867	523,867
Issuance Date January 2009 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computations of diluted weighted-average shares outstanding	9,259	9,259	9,259	9,259
Underwriter [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computations of diluted weighted-average shares outstanding	82,500		82,500
Series A Warrants to Purchase Shares of Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computations of diluted weighted-average shares outstanding	2,425,605		2,449,605
Series B Warrants to Purchase Shares of Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computations of diluted weighted-average shares outstanding	1,778,275

Revision_of_Prior_Year_Financi2

Revision of Prior Year Financial Statements - Schedule of Revised Prior Period Balances (Detail) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Current liabilities	$1,059,000		$1,289,785	$14,178,229
Total liabilities	21,370,000		19,586,000
Additional paid-in capital	70,679,000		59,141,404	19,235,512
Accumulated deficit	-81,989,000		-70,338,126	-57,100,511
Total stockholders' deficit	-11,303,000		-11,189,953	-37,864,463	-34,195,637
Liabilities and stockholders' deficit	10,067,000		8,395,925	1,586,691
Other income (expense)		-8,000	-3,948,578	-1,965
Net loss	-11,651,000	-834,000	-13,237,616	-3,707,243
Basic and diluted net loss per common share	($1.67)	($1.56)	($10.42)	($6.92)
Series A Warrant liability [Member]
Warrant liability	3,582,000		857,362
Series B Warrant liability [Member]
Warrant liability	14,180,000		17,438,731
Previously reported [Member]
Current liabilities			1,290,000
Total liabilities			18,729,000
Additional paid-in capital			60,636,000
Accumulated deficit			-70,975,000
Total stockholders' deficit			-10,330,000
Liabilities and stockholders' deficit			8,396,000
Other income (expense)			-4,585,000
Net loss			-13,875,000
Basic and diluted net loss per common share			($10.92)
Previously reported [Member] \| Series B Warrant liability [Member]
Warrant liability			17,439,000
Adjustment [Member]
Total liabilities			857,000
Additional paid-in capital			-1,494,000
Accumulated deficit			637,000
Total stockholders' deficit			-857,000
Other income (expense)			637,000
Net loss			637,000
Basic and diluted net loss per common share			$0.50
Adjustment [Member] \| Series A Warrant liability [Member]
Warrant liability			$857,000

Fair_Value_of_Financial_Instru2

Fair Value of Financial Instruments - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Series A Warrant liability [Member]
Liabilities
Warrant liability	$3,582,000	$857,362
Series B Warrant liability [Member]
Liabilities
Warrant liability	14,180,000	17,438,731
Series C Warrant liability [Member]
Liabilities
Warrant liability	2,549,000		1,464,877
Fair Value, Measurements, Recurring [Member] \| Convertible preferred stock warrant liability [Member]
Liabilities
Warrant liability	20,311,000	18,296,000	1,464,877
Fair Value, Measurements, Recurring [Member] \| Convertible preferred stock warrant liability [Member] \| Series A Warrant liability [Member]
Liabilities
Warrant liability	3,582,000	857,000
Fair Value, Measurements, Recurring [Member] \| Convertible preferred stock warrant liability [Member] \| Series B Warrant liability [Member]
Liabilities
Warrant liability	14,180,000	17,439,000
Fair Value, Measurements, Recurring [Member] \| Convertible preferred stock warrant liability [Member] \| Series C Warrant liability [Member]
Liabilities
Warrant liability	2,549,000
Fair Value, Measurements, Recurring [Member] \| Money market fund [Member]
Assets
Cash and cash equivalents	6,472,000	7,892,000	1,256,752
Fair Value, Measurements, Recurring [Member] \| Level 1 [Member] \| Convertible preferred stock warrant liability [Member]
Liabilities
Warrant liability	3,582,000	857,000
Fair Value, Measurements, Recurring [Member] \| Level 1 [Member] \| Convertible preferred stock warrant liability [Member] \| Series A Warrant liability [Member]
Liabilities
Warrant liability	3,582,000	857,000
Fair Value, Measurements, Recurring [Member] \| Level 1 [Member] \| Money market fund [Member]
Assets
Cash and cash equivalents	6,472,000	7,892,000	1,256,752
Fair Value, Measurements, Recurring [Member] \| Level 3 [Member] \| Convertible preferred stock warrant liability [Member]
Liabilities
Warrant liability	16,729,000	17,349,000	1,464,877
Fair Value, Measurements, Recurring [Member] \| Level 3 [Member] \| Convertible preferred stock warrant liability [Member] \| Series B Warrant liability [Member]
Liabilities
Warrant liability	14,180,000	17,439,000
Fair Value, Measurements, Recurring [Member] \| Level 3 [Member] \| Convertible preferred stock warrant liability [Member] \| Series C Warrant liability [Member]
Liabilities
Warrant liability	$2,549,000

Property_and_Equipment_Net_Sch

Property and Equipment, Net - Schedule of Property and Equipment (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Property and equipment, net	$44,000	$57,607	$63,167
Property, Plant and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross		202,441	218,519
Less accumulated depreciation and amortization		-144,834	-155,352
Property and equipment, net		57,607	63,167
Furniture and Fixtures [Member] \| Property, Plant and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross		170,811	180,238
Computer Hardware [Member] \| Property, Plant and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross		27,555	27,555
Leasehold Improvements [Member] \| Property, Plant and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross		$4,075	$10,726

Property_and_Equipment_Net_Add

Property and Equipment, Net - Additional Information (Detail) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Depreciation expense	$15,000	$7,000	$28,516	$42,114

Related_Party_Convertible_Prom1

Related Party Convertible Promissory Notes - Additional Information (Detail) (USD $)	3 Months Ended		12 Months Ended		0 Months Ended	1 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Nov. 18, 2014	Oct. 31, 2014	Aug. 31, 2014	Apr. 30, 2014
Debt Instrument [Line Items]
Debt instrument, percentage of share price			75.00%
Debt instrument, interest expense	$1,000	$388,000	$4,130,394	$2,860,267
Convertible preferred stock warrants, Fair Value				1,464,877	1,220,719
Beneficial conversion feature related to convertible promissory notes			1,723,984
Amortization of debt discount			4,128,863	2,860,267
IPO [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Estimated volatility rate					61.00%
Estimated liquidity term					4 years 6 months
Estimated risk-free interest rate					1.50%
IPO [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Estimated volatility rate					71.20%
Estimated liquidity term					7 years 6 months
Estimated risk-free interest rate					2.09%
2010 and 2012 Convertible Promissory Notes [Member]
Debt Instrument [Line Items]
Principal amount of convertible promissory notes			10,200,413
Debt instrument, interest rate			12.00%
Debt instrument, interest expense			1,416,554	2,860,267
Convertible preferred stock warrants, Fair Value				1,422,433	1,217,808
2010 and 2012 Convertible Promissory Notes [Member] \| IPO [Member]
Debt Instrument [Line Items]
Aggregate principal amount and accrued interest outstanding					15,410,110
2010 and 2012 Convertible Promissory Notes [Member] \| IPO [Member] \| Common Stock [Member]
Debt Instrument [Line Items]
Convertible promissory notes converted into units/shares			3,165,887		3,165,887
Convertible promissory notes, conversion price					4.87
Debt instrument, percentage of share price					75.00%
2014 Convertible Promissory Notes [Member]
Debt Instrument [Line Items]
Principal amount of convertible promissory notes						493,407	249,693	1,747,681
Debt instrument, interest rate						2.00%	2.00%	2.00%
Beneficial conversion feature related to convertible promissory notes						239,872	136,705	1,347,406
Debt instrument, interest expense					21,348
Amortization of debt discount					835,509
2014 Convertible Promissory Notes [Member] \| IPO [Member]
Debt Instrument [Line Items]
Principal amount of convertible promissory notes					2,512,119
Convertible promissory notes converted into units/shares					552,105
Convertible promissory notes, conversion price						$4.55	$4.55	$4.55
Debt instrument, percentage of share price						70.00%	70.00%	70.00%
Amortization of debt discount			1,855,452
IPO price per unit					6.5
2014 Convertible Promissory Notes [Member] \| IPO [Member] \| Common Stock [Member]
Debt Instrument [Line Items]
Convertible promissory notes converted into units/shares			552,105
2014 Convertible Promissory Notes [Member] \| Warrants to purchase preferred stock, issued with convertible notes [Member]
Debt Instrument [Line Items]
Convertible promissory notes, conversion price						$16.20	$16.20	$16.20
Debt instrument, percentage of share price						75.00%	75.00%	75.00%
Debt instrument, percentage of unpaid principal						25.00%	25.00%	25.00%
Convertible preferred stock warrants, Fair Value						$253,535	$113,295	$600,148
Warrant expiration term						10 years	10 years	10 years
2014 Convertible Promissory Notes [Member] \| Warrants to purchase preferred stock, issued with convertible notes [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Estimated volatility rate						35.00%	35.00%	35.00%
Estimated liquidity term						1 year	1 year 3 months	1 year 6 months
Estimated risk-free interest rate						0.20%	0.20%	0.20%
2014 Convertible Promissory Notes [Member] \| Warrants to purchase preferred stock, issued with convertible notes [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Estimated volatility rate						60.00%	60.00%	60.00%
Estimated liquidity term						5 years	5 years	5 years
Estimated risk-free interest rate						2.26%	2.26%	2.60%
2014 Convertible Promissory Notes [Member] \| Shares of common stock [Member] \| IPO [Member]
Debt Instrument [Line Items]
Convertible promissory notes converted into units/shares					552,105
2014 Convertible Promissory Notes [Member] \| Series A Warrants to Purchase Shares of Common Stock [Member] \| IPO [Member]
Debt Instrument [Line Items]
Convertible promissory notes converted into units/shares					552,105
2014 Convertible Promissory Notes [Member] \| Series B Warrants to Purchase Shares of Common Stock [Member] \| IPO [Member]
Debt Instrument [Line Items]
Convertible promissory notes converted into units/shares					552,105

Convertible_Preferred_Stock_Wa2

Convertible Preferred Stock Warrants - Additional Information (Detail) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Nov. 18, 2014
Class of Warrant or Right [Line Items]
Debt instrument, percentage of share price			75.00%
Amount of unpaid principal percentage			25.00%
Warrants expiration period			10 years
Change in fair value of warrants recorded as other (income)expense	$6,174,000	($246,000)	$3,941,335	$105,320
Gain on fair value of preferred stock warrant liability			967,234
Convertible preferred stock warrants, Number of shares underlying warrant				1,464,877	1,220,719
Issuance Date January 2009 [Member]
Class of Warrant or Right [Line Items]
Warrants convert into common stock, exercise price				$21.60
Convertible preferred stock warrants, Number of shares underlying warrant				42,444	2,911
2010 and 2012 Convertible Promissory Notes [Member]
Class of Warrant or Right [Line Items]
Convertible preferred stock warrants, Number of shares underlying warrant				1,422,433	1,217,808
2010 and 2012 Convertible Promissory Notes [Member] \| IPO [Member] \| Issuance Date January 2009 [Member]
Class of Warrant or Right [Line Items]
Warrants convert into common stock, exercise price			$21.60
Convertible preferred stock warrants, Number of shares underlying warrant			9,259
2010 and 2012 Convertible Promissory Notes [Member] \| IPO [Member] \| Shares of common stock [Member]
Class of Warrant or Right [Line Items]
Change in fair value of warrants recorded as other (income)expense			$244,151
Debt conversion, warrants issued			523,867
Warrants convert into common stock, exercise price			$4.87
Series C Convertible Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Debt instrument, conversion price per share			$16.20

Convertible_Preferred_Stock_Wa3

Convertible Preferred Stock Warrants - Fair Value of Convertible Preferred Stock Warrant Liability (Detail) (USD $)	0 Months Ended	12 Months Ended
	Nov. 18, 2014	Dec. 31, 2013
IPO [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Expected dividend yield	0.00%
Stock Price	$4
Convertible preferred stock warrant liability [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Expected dividend yield		0.00%
Minimum [Member] \| IPO [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Volatility	61.00%
Expected Term (years)	4 years 6 months
Risk-free rate	1.50%
Exercise Price	$4.87
Minimum [Member] \| Convertible preferred stock warrant liability [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Volatility		38.00%
Expected Term (years)		9 months
Risk-free rate		0.12%
Maximum [Member] \| IPO [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Volatility	71.20%
Expected Term (years)	7 years 6 months
Risk-free rate	2.09%
Exercise Price	$21.60
Maximum [Member] \| Convertible preferred stock warrant liability [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Volatility		47.00%
Expected Term (years)		2 years
Risk-free rate		0.38%

Convertible_Preferred_Stock_Wa4

Convertible Preferred Stock Warrants - Summary of Outstanding Convertible Preferred Stock Warrants (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 31, 2015	Nov. 18, 2014
Class of Warrant or Right [Line Items]
Convertible preferred stock warrants, Fair Value	$1,464,877		$1,220,719
Issuance Date January 2009 [Member]
Class of Warrant or Right [Line Items]
Warrants, Contractual Term	10 years
Convertible preferred stock warrants, Exercise price per share	$21.60
Convertible preferred stock warrants, Number of shares underlying warrant	9,259	9,259
Convertible preferred stock warrants, Fair Value	42,444		2,911
2010 and 2012 Convertible Promissory Notes [Member]
Class of Warrant or Right [Line Items]
Warrants, Contractual Term	10 years
Convertible preferred stock warrants, Fair Value	$1,422,433		$1,217,808

Warrant_Liabilities_Additional

Warrant Liabilities - Additional Information (Detail) (USD $)	3 Months Ended		12 Months Ended		0 Months Ended	3 Months Ended	0 Months Ended		1 Months Ended	11 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Nov. 18, 2014	Dec. 31, 2014	Mar. 06, 2015	Mar. 05, 2015	Mar. 31, 2015	Feb. 12, 2016
Class of Warrant or Right [Line Items]
Change in fair value of warrants recorded as other (income) expense	$6,174,000	($246,000)	$3,941,335	$105,320
Registration statements description	The Company is required to comply with certain requirement to maintain the effectiveness of a registration statement for the offer and sale of these securities. The Warrant contracts further provide for the payment of liquidated damages at an amount per month equal to 1% of the aggregate VWAP of the shares into which each Warrant is convertible into in the event that the Company is unable to maintain the effectiveness of a registration
Fair value of warrants outstanding				1,464,877	1,220,719
IPO [Member] \| 2014 Convertible Promissory Notes [Member]
Class of Warrant or Right [Line Items]
Convertible promissory notes converted into units/shares					552,105
Series A Warrants to Purchase Shares of Common Stock [Member]
Class of Warrant or Right [Line Items]
Warrants term						5 years
Series A Warrants to Purchase Shares of Common Stock [Member] \| 2014 Convertible Promissory Notes [Member]
Class of Warrant or Right [Line Items]
Exercise price of warrants exercised			$6.50			6.5
Series A Warrants to Purchase Shares of Common Stock [Member] \| IPO [Member]
Class of Warrant or Right [Line Items]
Exercise price of warrants exercised					6.5
Warrants term	5 years
Number of common stock purchased upon issuance of warrants					2,449,605
Warrants outstanding					2,449,605
Series A Warrants to Purchase Shares of Common Stock [Member] \| IPO [Member] \| 2014 Convertible Promissory Notes [Member]
Class of Warrant or Right [Line Items]
Convertible promissory notes converted into units/shares					552,105
Series A Warrant liability [Member]
Class of Warrant or Right [Line Items]
Exercise price of warrants exercised			$6.50			6.5
Proceeds from issuance of warrants in IPO			9,488
Change in fair value of warrants recorded as other (income) expense	-2,800,000
Warrants exercised	24,000								24,000
Warrants outstanding	2,425,605		2,449,605			2,449,605			2,425,605
Fair value of warrants outstanding	3,600,000		857,362		1,494,259	857,362			3,600,000
Gross proceeds upon exercise of warrants	156,000						200,000
Series A Warrant liability [Member] \| IPO [Member]
Class of Warrant or Right [Line Items]
Change in fair value of warrants recorded as other (income) expense			636,897
Series B Warrant liability [Member]
Class of Warrant or Right [Line Items]
Exercise price of warrants exercised	$6.50							$6.50	$6.50
Proceeds from issuance of warrants in IPO			9,488
Change in fair value of warrants recorded as other (income) expense	-1,500,000							-2,300,000
Warrants exercised								589,510
Warrants outstanding	1,778,275		2,449,605			2,449,605			1,778,275
Fair value of warrants outstanding	14,180,000		17,438,731		11,649,106	17,438,731		6,700,000	14,180,000
Warrants cashless exercised	52,255
Gross proceeds upon exercise of warrants								3,800,000
Series B Warrant liability [Member] \| IPO [Member]
Class of Warrant or Right [Line Items]
Change in fair value of warrants recorded as other (income) expense			-5,789,625
Series C Warrant liability [Member]
Class of Warrant or Right [Line Items]
Exercise price of warrants exercised								$6.25
Warrants term								5 years
Change in fair value of warrants recorded as other (income) expense								-3,000,000	500,000
Number of common stock purchased upon issuance of warrants								589,510
Fair value of warrants outstanding	$2,500,000							$3,000,000	$2,500,000
Warrants expiry date								5-Mar-20
Shares of common stock [Member] \| IPO [Member] \| 2014 Convertible Promissory Notes [Member]
Class of Warrant or Right [Line Items]
Convertible promissory notes converted into units/shares					552,105
Series B Warrants to Purchase Shares of Common Stock [Member]
Class of Warrant or Right [Line Items]
Number of common stock purchased upon issuance of warrants	2,449,605								2,449,605
Series B Warrants to Purchase Shares of Common Stock [Member] \| IPO [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding					2,449,605
Series B Warrants to Purchase Shares of Common Stock [Member] \| IPO [Member] \| 2014 Convertible Promissory Notes [Member]
Class of Warrant or Right [Line Items]
Convertible promissory notes converted into units/shares					552,105
Series A warrants to purchase common stock [Member] \| IPO [Member]
Class of Warrant or Right [Line Items]
Warrants issued in connection with IPO					1,897,500
Scenario Forecast [Member] \| Series B Warrants to Purchase Shares of Common Stock [Member]
Class of Warrant or Right [Line Items]
Decrease in common stock market price										$6.50
Scenario Forecast [Member] \| Series B Warrants to Purchase Common Stock [Member]
Class of Warrant or Right [Line Items]
Decrease in common stock market price										$6.50

Warrant_Liabilities_Summary_of

Warrant Liabilities - Summary of Outstanding Series B Warrants and Fair Market Values (Detail) (USD $)	12 Months Ended	3 Months Ended
	Dec. 31, 2014	Mar. 31, 2015	Nov. 18, 2014	Dec. 31, 2013	Mar. 05, 2015
Class of Warrant or Right [Line Items]
Warrants, Fair value			$1,220,719	$1,464,877
Warrants, Fair value			1,220,719	1,464,877
Series A Warrant liability [Member]
Class of Warrant or Right [Line Items]
Warrants, Contractual Term	5 years
Warrants, Exercise price per share	$6.50
Warrants, Contractual Term	5 years
Warrants, Number of warrants	2,449,605	2,425,605
Warrants, Shares underlying warrants	2449605
Warrants, Fair value	857,362	3,600,000	1,494,259
Warrants, umber of warrants	2,449,605	2,425,605
Warrants, Fair value	857,362	3,600,000	1,494,259
Series B Warrant liability [Member]
Class of Warrant or Right [Line Items]
Warrants, Contractual Term		15 months
Warrants, Exercise price per share		$6.50			$6.50
Warrants, Contractual Term		15 months
Warrants, Number of warrants	2,449,605	1,778,275
Warrants, Fair value	17,438,731	14,180,000	11,649,106		6,700,000
Warrants, umber of warrants	2,449,605	1,778,275
Warrants, Fair value	$17,438,731	$14,180,000	$11,649,106		$6,700,000

Warrant_Liabilities_Fair_Value

Warrant Liabilities - Fair Value of Convertible Preferred Stock Warrant Liability (Detail)	0 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Nov. 18, 2014	Mar. 04, 2015
Series B Warrant liability [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Volatility	100.00%	86.60%	64.00%
Expected Term (years)	10 months 13 days	1 year 1 month 6 days	1 year 3 months
Expected dividend yield	0.00%	0.00%	0.00%
Risk-free rate	0.26%	0.26%	0.20%
Series B Warrant liability [Member] \| Previously reported [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Volatility		86.00%
Series C Warrant liability [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Volatility	86.00%			86.00%
Expected Term (years)	4 years 11 months 5 days			5 years
Expected dividend yield	0.00%			0.00%
Risk-free rate	1.35%			1.37%

Credit_Facility_Additional_Inf

Credit Facility - Additional Information (Detail) (USD $)	3 Months Ended	12 Months Ended
Credit Facility - Additional Information (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014	Oct. 31, 2014	Sep. 29, 2014
Line of Credit Facility [Line Items]
Line of credit amount				$100,000
Line of credit, fixed interest rate per annum	6.00%	6.00%
Line of credit, interest rate description	The line of credit bears a fixed interest rate of 6.0% per annum simple interest.	The line of credit bears a fixed interest rate of 6.0% per annum simple interest.
Line of credit, repayment term	2 years	2 years
Line of credit facility, initiation date	29-Sep-14	29-Sep-14
Amount of line of credit			100,000
Repayment of line of credit	$102,000

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Detail) (USD $)	3 Months Ended		12 Months Ended		9 Months Ended	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Sep. 30, 2014	Dec. 31, 2010	Feb. 02, 2015
	Mar. 31, 2015	Mar. 31, 2014	Facilities	Dec. 31, 2013	Sep. 30, 2014	Dec. 31, 2010	Feb. 02, 2015
Loss Contingencies [Line Items]
Non-cancelable operating lease agreement expiration date	2015-05		2015-05
Number of previously leased facilities			2
Rent expense	$62,000	$57,000	$230,000	$304,000
Future minimum commitment under non-cancelable operating lease			18,000				22,000
Lease expiration extended date	2018-06
Lease payment, description	The amendment provides for monthly lease payments of $22,000 beginning in June 2015, with modest increases in the following two years.
Milestone Payments [Member] \| BioMedical Drug Development, Inc. [Member]
Loss Contingencies [Line Items]
Development and sales-related milestone payments, maximum	200,000		200,000
Payments made and liabilities incurred under asset purchase agreement			0	0	0
Outstanding payments	0		0	0
Facility one [Member]
Loss Contingencies [Line Items]
Non-cancelable operating lease agreement expiration date			2014-01
Facility two [Member]
Loss Contingencies [Line Items]
Non-cancelable operating lease agreement expiration date			2014-05
Intellectual property [Member] \| BioMedical Drug Development, Inc. [Member]
Loss Contingencies [Line Items]
Acquisition of intellectual property						$150,000

Capital_Stock_Additional_Infor

Capital Stock - Additional Information (Detail) (USD $)	12 Months Ended	0 Months Ended
Capital Stock - Additional Information (Detail) (USD $)	Dec. 31, 2014	Nov. 18, 2014	Mar. 31, 2015	Dec. 31, 2013
Class of Stock [Line Items]
Common stock, shares authorized	100,000,000		100,000,000	10,000,000
Common stock, par value	$0.00		$0.00	$0.00
Common stock, shares issued	6,769,106	6,769,106	7,448,389	535,685
Common stock, shares outstanding	6,769,106	535,685	7,448,389	535,685
Common stock, vote description	Each share of common stock is entitled to one vote. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when and if declared by the Board of Directors, subject to the prior rights of all classes of stock outstanding. The holders of common stock, voting as a separate class, are entitled to elect one member of the Board of Directors.
Convertible preferred stock, shares authorized				1,860,000
IPO [Member]
Class of Stock [Line Items]
Common stock, shares issued		6,769,106
Common stock, shares outstanding		6,769,106
Common Stock [Member]
Class of Stock [Line Items]
Common stock issued upon conversion of convertible preferred stock		865,429
Common Stock [Member] \| IPO [Member]
Class of Stock [Line Items]
Common stock issued upon conversion of convertible preferred stock	865,429	865,429
Conversion ratio, description	Conversion ratio of one to one
Conversion ratio		1
Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, shares authorized				1,860,000

Capital_Stock_Summary_of_Commo

Capital Stock - Summary of Common Stock Issued and Outstanding (Detail)	0 Months Ended	12 Months Ended
	Nov. 18, 2014	Dec. 31, 2014	Mar. 31, 2015	Dec. 31, 2013
Legacy Shareholders	535,685	6,769,106	7,448,389	535,685
Common stock, issued	6,769,106	6,769,106	7,448,389	535,685
IPO [Member]
Legacy Shareholders	6,769,106
Common stock, issued	6,769,106
2014 Convertible Promissory Notes [Member] \| IPO [Member]
Debt conversion, shares issued	552,105
Units [Member] \| IPO [Member]
Issued in connection with the IPO	1,650,000	1,650,000
Units [Member] \| 2014 Convertible Promissory Notes [Member]
Debt conversion, shares issued	552,105
Units [Member] \| 2014 Convertible Promissory Notes [Member] \| IPO [Member]
Debt conversion, shares issued		552,105
Common Stock [Member]
Issued in connection with the IPO		1,650,000
Common stock issued upon conversion of convertible preferred stock	865,429
Common Stock [Member] \| IPO [Member]
Issued in connection with the IPO		1,650,000
Common stock issued upon conversion of convertible preferred stock	865,429	865,429
Common Stock [Member] \| 2014 Convertible Promissory Notes [Member]
Common stock issued upon conversion of convertible preferred stock		552,105
Common Stock [Member] \| 2014 Convertible Promissory Notes [Member] \| IPO [Member]
Debt conversion, shares issued		552,105
Common Stock [Member] \| 2010 and 2012 Convertible Promissory Notes [Member]
Common stock issued upon conversion of convertible preferred stock		3,165,887
Common Stock [Member] \| 2010 and 2012 Convertible Promissory Notes [Member] \| IPO [Member]
Debt conversion, shares issued	3,165,887	3,165,887

Capital_Stock_Summary_of_Conve

Capital Stock - Summary of Convertible Preferred Stock (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Class of Stock [Line Items]
Shares Authorized		1,860,000
Shares Outstanding		865,429
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Par Value	$0.00	$0.00
Shares Authorized	40,000	40,000
Shares Outstanding	0	31,250
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Par Value	$0.00	$0.00
Shares Authorized	320,000	320,000
Shares Outstanding	0	119,140
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Par Value	$0.00	$0.00
Shares Authorized	1,500,000	1,500,000
Shares Outstanding	0	715,039

Stockholders_Deficit_Stock_Opt

Stockholders' Deficit - Stock Option Plan - Additional Information (Detail) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$401,000	$11,000	$345,435	$38,417
Number of options exercised				0
Number of options granted			926,384	0
Number of shares, vested			578,889	232,302
Weighted-average exercise price			$5.58	$3.36
Weighted-average contractual life			7 years 5 months 16 days	3 years 10 months 10 days
Weighted average grant date fair value per option			$0.66	$0.10
Stock options outstanding, intrinsic value			20,228
Stock options outstanding, weighted average remaining contractual term			8 years 8 months 1 day
Future stock-based compensation for unvested employee options granted and outstanding	900,000
Annual increases in the number of shares available for issuance , percentage of outstanding common stock	1.00%
Purchases by employees under ESPP	0
Warrants to Purchase Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants cashless exercised	43,720
Issuance of shares upon cashless exercise warrants	13,407
Warrants to Purchase Stock [Member] \| 2010 and 2012 Convertible Promissory Notes [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants outstanding	480,147
Issuance Date January 2009 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants outstanding	9,259			9,259
Underwriter [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants outstanding	82,500
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for sale under the ESPP	139,839
Annual increases in the number of shares available for issuance, number of shares	279,680
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option compensation, description	For individuals holding more than 10% of the voting rights of all classes of stock, the exercise price of an option will not be less than 110% of fair value.		For individuals holding more than 10% of the voting rights of all classes of stock, the exercise price of an option will not be less than 110% of fair value.
Vesting period	4 years		4 years
Stock-based compensation expense	401,000	11,000	345,435	38,417
Income tax benefits recognized from stock-based compensation	0	0	0	0
Number of options exercised	2,083
Number of options granted	407,013		926,384
Future stock-based compensation for unvested employee options granted and outstanding			$539,087
Future stock-based compensation, requisite service period	3 years 7 months 6 days		3 years 10 months 17 days
Shares available for sale under the ESPP	487,790		606,061	124,824
Annual increases in the number of shares available for issuance, number of shares	270,764
NSO [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of fair market value	85.00%		85.00%
Minimum [Member] \| Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of fair market value	110.00%		110.00%
Maximum [Member] \| Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Contractual term of option	10 years		10 years
Maximum [Member] \| ISOs [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Contractual term of option	5 years		5 years

Stockholders_Deficit_Summary_o

Stockholders' Deficit - Summary of Stock Based Compensation Expense (Detail) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock compensation expense	$401,000	$11,000	$345,435	$38,417
Research and development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock compensation expense	50,000	9,000	64,020	14,431
Sales and marketing [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock compensation expense	20,000		8,335
General and administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock compensation expense	$331,000	$2,000	$273,080	$23,986

Stockholders_Deficit_Schedule_

Stockholders' Deficit - Schedule of Fair Value of Award Granted Using Black-Scholes Option Pricing Model (Detail) (Stock Options [Member])	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate, minimum	1.50%	1.60%	1.60%
Risk-free interest rate, maximum	1.60%	1.80%	1.80%
Volatility, minimum	57.00%	62.00%	43.00%
Volatility, maximum	68.00%	80.00%	59.00%
Dividend rate	0.00%	0.00%	0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life (years)	5 years 6 months	5 years 9 months 18 days	5 years 9 months 18 days
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life (years)	6 years 1 month 6 days	6 years 1 month 6 days	6 years 1 month 6 days

Stockholders_Deficit_Summary_o1

Stockholders' Deficit - Summary of Stock Option Transactions (Detail) (USD $)	12 Months Ended		3 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Granted	926,384	0
Number of Shares, Exercised		0
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Grant Date Fair Value Per Option, Granted	1.03
Options Available, Authorized			270,764
Weighted Average Grant Date Fair Value Per Option, Forfeited	1.03
Options Available, Beginning balance	124,824		606,061
Options Available, Granted	-926,384		-407,013
Options Available, Forfeited	93,979		17,977
Options Available, Ending balance	606,061		487,790
Number of Shares, Outstanding, Beginning balance	239,606		1,072,011
Number of Shares, Granted	926,384		407,013
Number of Shares, Exercised			-2,083
Number of Shares, Forfeited	-93,979		-17,977
Number of Shares, Outstanding, Ending balance	1,072,011		1,458,964
Average Exercise Price, Beginning balance	3.36		$6.34
Average Exercise Price, Granted	7.15		$1.80
Average Exercise Price, Exercised			$5.76
Average Exercise Price, Forfeited	6.75		$4.94
Average Exercise Price, Ending balance	6.34		$5.09
Stock Options [Member] \| 2014 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Available, Authorized	1,437,165
Stock Options [Member] \| Closed 2010 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Available, Expired	-123,523

GSK_License_Agreement_Addition

GSK License Agreement - Additional Information (Detail) (GlaxoSmithKline [Member], USD $)	12 Months Ended
	Dec. 31, 2013
GlaxoSmithKline [Member]
Deferred Revenue Arrangement [Line Items]
Deferred revenue recognized	$3,000,000

Income_Taxes_Reconciliation_of

Income Taxes - Reconciliation of Income Tax Expense by Applying Statutory U.S. Federal Income Tax Rate to Income Before Income Taxes (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax Contingency [Line Items]
Tax on the loss before income tax expense computed at the federal statutory rate of 34%	($4,500,789)	($1,260,190)
State tax (benefit) at statutory rate, net of federal benefit	-13,020	43,265
Change in Valuation Allowance	1,578,347	779,869
Change in research and development credits	316,311	-71,856
Change in fair value of warrants	2,744,492
Other	-125,341	508,912
Income tax expense	$0	$0
Effective income tax rate	0.00%	0.00%

Income_Taxes_Reconciliation_of1

Income Taxes - Reconciliation of Income Tax Expense by Applying Statutory U.S. Federal Income Tax Rate to Income Before Income Taxes (Parenthetical) (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax Contingency [Line Items]
Federal statutory rate percentage	34.00%	34.00%

Income_Taxes_Significant_Compo

Income Taxes - Significant Components of Company's Deferred Tax Assets and Liabilities (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current Deferred Tax Assets:
Accruals	$71,953	$36,571
Non-Current Deferred Tax Assets:
Net Operating Loss Carryforwards	22,125,807	20,124,059
Research and development credits	1,345,833	1,792,798
Intangible Assets	46,784	48,733
Fixed Assets	-10,505	-636
Total Non-Current Deferred Tax Assets	23,507,919	21,964,954
Total Deferred Tax Assets	23,579,872	22,001,525
Valuation Allowance	-23,579,872	-22,001,525
Net Deferred Tax Assets	$0	$0

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	12 Months Ended
Income Taxes - Additional Information (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Income Tax Contingency [Line Items]
Increase in the valuation allowance	$1,578,347
Net operating loss carry-forwards federal	56,626,541
Net operating loss carry-forwards state	49,238,708
Federal research and development tax credits	1,298,450
State research and development tax credits	945,710
Federal research and development tax credits expiration year	2024
Unrecognized tax benefits impacting effective tax rate	0	0
Unrecognized tax benefit offset by change in valuation allowance	$673,248
Income tax examination, description	In the U.S. federal jurisdiction, tax years 1999 forward remain open to examination, and in the state tax jurisdiction, years 2004 forward remain open to examination.
U.S. Federal Jurisdiction [Member]
Income Tax Contingency [Line Items]
Federal and state net operating loss carry-forwards, expiring year	2019
Open tax year	1999
State Tax Jurisdiction [Member]
Income Tax Contingency [Line Items]
Federal and state net operating loss carry-forwards, expiring year	2015
Open tax year	2004

Income_Taxes_Summary_of_Gross_

Income Taxes - Summary of Gross Unrecognized Tax Benefits (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax Contingency [Line Items]
Beginning balance	$0
Increase related to prior year tax positions	628,383
Decreases related to prior year tax positions	0	0
Increase related to Current year tax positions	44,864
Decreases related to current year tax positions	0	0
Ending Balance	$673,247	$0

Defined_Contribution_Plan_Addi

Defined Contribution Plan - Additional Information (Detail)	12 Months Ended
Defined Contribution Plan - Additional Information (Detail)	Dec. 31, 2014
Defined contribution plan description	The Company sponsors a 401(k) Plan, which stipulates that eligible employees can elect to contribute to the 401(k) Plan, subject to certain limitations of eligible compensation. The Company may match employee contributions in amounts to be determined at the Company's sole discretion. To date, the Company has not made any matching contributions.

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail) (USD $)	3 Months Ended	0 Months Ended
Subsequent Events - Additional Information (Detail) (USD $)	Mar. 31, 2015	Mar. 05, 2015	Feb. 02, 2015	Jan. 09, 2015	Apr. 01, 2015	Dec. 31, 2014
Subsequent Event [Line Items]
Lease agreement, date	2018-06
Monthly lease payments			$22,000			$18,000
Lease payment, description	The amendment provides for monthly lease payments of $22,000 beginning in June 2015, with modest increases in the following two years.
Series B Warrant liability [Member]
Subsequent Event [Line Items]
Exercise price of warrants exercised	$6.50	$6.50
Warrants cashless exercised	52,255
Series C Warrant liability [Member]
Subsequent Event [Line Items]
Number of shares purchased on exercise of warrants		589,510
Exercise price of warrants exercised		$6.25
Warrants expiry date		5-Mar-20
Warrants term		5 years
Subsequent event [Member]
Subsequent Event [Line Items]
Gifts to charitable organization				210,000
Lease agreement, date			2018-06
Monthly lease payments			21,719
Lease payment, description			The amendment provides for monthly lease payments of $21,719 for the first year starting in June 2015, with modest increases in the following two years.
Warrants exercisable date		5-Mar-15
Subsequent event [Member] \| Common Stock [Member]
Subsequent Event [Line Items]
Issuance of shares upon cashless exercise warrants					63,095
Subsequent event [Member] \| Series B Warrant liability [Member]
Subsequent Event [Line Items]
Number of shares purchased on exercise of warrants		589,510
Exercise price of warrants exercised		$6.50
Gross proceeds upon exercise of warrants		$3,800,000
Warrants cashless exercised					161,320
Subsequent event [Member] \| Series C Warrant liability [Member]
Subsequent Event [Line Items]
Number of shares purchased on exercise of warrants		589,510
Exercise price of warrants exercised		$6.25
Warrants expiry date		5-Mar-20

Liquidity_Financial_Condition_1

Liquidity, Financial Condition and Management's Plans - Additional Information (Detail) (USD $)	3 Months Ended		12 Months Ended		0 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Mar. 05, 2015	Mar. 06, 2015	Nov. 18, 2014
Liquidity And Managements Plans [Line Items]
Accumulated deficit	($81,989,000)		($70,338,126)	($57,100,511)
Non-cash charges relating to the fair value of derivative liabilities	-9,200,000
Stock based compensation	401,000	11,000	345,435	38,417
Working capital	9,000,000
Net cash used in operating activities	-1,809,000	-509,000	-4,484,362	-885,218
Net loss	-11,651,000	-834,000	-13,237,616	-3,707,243
Net proceeds after deducting underwriting discounts and commissions and IPO related expenses			10,727,475
Proceeds from exercise of stock options	12,000
Private Placement Series B Warrants [Member]
Liquidity And Managements Plans [Line Items]
Proceed from Exercise of warrants to purchase of common stock	3,832,000				3,800,000
Series A Warrant liability [Member]
Liquidity And Managements Plans [Line Items]
Proceed from Exercise of warrants to purchase of common stock	156,000					200,000
IPO [Member]
Liquidity And Managements Plans [Line Items]
Net proceeds after deducting underwriting discounts and commissions and IPO related expenses							8,000,000
IPO [Member] \| Units [Member]
Liquidity And Managements Plans [Line Items]
Description of units issued	1,650,000 units, each of which consisted of one share of common stock, one Series A Warrant and one Series B Warrant.		1,650,000 units (each unit consisting of one share of common stock, one Series A warrant and one Series B warrant)
Number of shares issued			1,650,000				1,650,000
Offering price per unit							$6.50
Net proceeds after deducting underwriting discounts and commissions and IPO related expenses			$10,708,500				$8,000,000

Fair_Value_of_Financial_Instru3

Fair Value of Financial Instruments - Summary of Changes in Fair Value of Level1 and Level 3 Financial Instruments (Detail) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014	Mar. 05, 2015
Series A Warrant liability [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at the beginning of period, in shares		2,449,605
De-recognition of Warrant liability upon exercise, in shares	-24,000
Balance at the end of period, in shares	2,425,605	2,449,605
Series A Warrant liability [Member] \| Common stock warrant liability [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at the beginning of period, in shares	2,449,605
De-recognition of Warrant liability upon exercise, in shares	-24,000
Balance at the end of period, in shares	2,425,605
Balance at the beginning of period	$857
Change in value of Warrant	2,767
De-recognition of Warrant liability upon exercise	-42
Balance at end of period	3,582
Series B Warrant liability [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at the beginning of period, in shares		2,449,605
De-recognition of Warrant liability upon exercise, in shares			-589,510
Balance at the end of period, in shares	1,778,275	2,449,605
Series B Warrant liability [Member] \| Common stock warrant liability [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at the beginning of period, in shares	2,449,605
Balance at the end of period, in shares	1,778,275
Balance at the beginning of period	17,439
Change in value of Warrant	3,909
Balance at end of period	14,180
Series B Warrant liability [Member] \| Common stock warrant liability [Member] \| Cash Exercise [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
De-recognition of Warrant liability upon exercise, in shares	-589,510
De-recognition of Warrant liability upon exercise	-6,430
Series B Warrant liability [Member] \| Common stock warrant liability [Member] \| Other Cash Exercise [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
De-recognition of Warrant liability upon exercise, in shares	-29,097
De-recognition of Warrant liability upon exercise	-317
Series B Warrant liability [Member] \| Common stock warrant liability [Member] \| Cash Less Exercise [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
De-recognition of Warrant liability upon exercise, in shares	-52,255
De-recognition of Warrant liability upon exercise	-418
Series B Warrant liability [Member] \| Common stock warrant liability [Member] \| Warrants contributed back to the company [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
De-recognition of Warrant liability upon exercise, in shares	-468
De-recognition of Warrant liability upon exercise	-3
Series C Warrant liability [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Record Series C Warrant Liability			589,510
Series C Warrant liability [Member] \| Common stock warrant liability [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Record Series C Warrant Liability	589,510
Balance at the end of period, in shares	589,510
Change in value of Warrant	-501
Record Series C Warrant Liability	3,050
Balance at end of period	$2,549

Fair_Value_of_Financial_Instru4

Fair Value of Financial Instruments - Summary of Changes in Fair Value of Level1 and Level 3 Financial Instruments (Parenthetical) (Detail) (Common stock warrant liability [Member], Series B Warrant liability [Member])	3 Months Ended
	Mar. 31, 2015
Cash Exercise [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
De-recognition of Warrant liability upon exercise, shares issued	589,510
Other Cash Exercise [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
De-recognition of Warrant liability upon exercise, shares issued	29,097
Cash Less Exercise [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
De-recognition of Warrant liability upon exercise, shares issued	21,186

Net_Loss_per_Share_Schedule_of

Net Loss per Share - Schedule of Calculation of Basic Earnings per Share and Diluted Earnings per Share (Detail) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Net loss	($11,651,000)	($834,000)	($13,237,616)	($3,707,243)
Weighted-average shares used in computing basic and diluted net loss per common share	6,965,483	535,685	1,270,033	535,648
Basic and diluted net loss per common share	($1.67)	($1.56)	($10.42)	($6.92)

Net_Loss_per_Share_Schedule_of1

Net Loss per Share - Schedule of Potentially Dilutive Securities Outstanding Excluded from Computations of Diluted Weighted-Average Shares Outstanding (Detail)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computations of diluted weighted-average shares outstanding		865,429		865,429
Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computations of diluted weighted-average shares outstanding	1,458,964	228,223	1,072,011	239,606
Warrants to Purchase Stock [Member] \| 2010 and 2012 Convertible Promissory Notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computations of diluted weighted-average shares outstanding	480,147	523,867	523,867
Issuance Date January 2009 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computations of diluted weighted-average shares outstanding	9,259	9,259	9,259	9,259
Underwriter [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computations of diluted weighted-average shares outstanding	82,500		82,500
Series A Warrants to Purchase Shares of Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computations of diluted weighted-average shares outstanding	2,425,605		2,449,605
Series B Warrants to Purchase Shares of Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computations of diluted weighted-average shares outstanding	1,778,275
Series C Warrant To Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computations of diluted weighted-average shares outstanding	589,510